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Abstract Arterial spin labeling (ASL) is a non-invasive
MRI technique to measure cerebral blood flow (CBF). This
review provides a practical guide and overview of the clin-
ical applications of ASL of the brain, as well its potential
pitfalls. The technical and physiological background is also
addressed. At present, main areas of interest are cerebrovas-
cular disease, dementia and neuro-oncology. In cerebrovas-
cular disease, ASL is of particular interest owing to its quan-
titative nature and its capability to determine cerebral arte-
rial territories. In acute stroke, the source of the collateral
blood supply in the penumbra may be visualised. In chronic
cerebrovascular disease, the extent and severity of compro-
mised cerebral perfusion can be visualised, which may be
used to guide therapeutic or preventative intervention. ASL
has potential for the detection and follow-up of arteriove-
nous malformations. In the workup of dementia patients,
ASL is proposed as a diagnostic alternative to PET. It can
easily be added to the routinely performed structural MRI
examination. In patients with established Alzheimer’s
disease and frontotemporal dementia, hypoperfusion pat-
terns are seen that are similar to hypometabolism patterns
seen with PET. Studies on ASL in brain tumour imaging
indicate a high correlation between areas of increased CBF
as measured with ASL and increased cerebral blood volume
as measured with dynamic susceptibility contrast-enhanced
perfusion imaging. Major advantages of ASL for brain tu-
mour imaging are the fact that CBF measurements are not
influenced by breakdown of the blood–brain barrier, as well
as its quantitative nature, facilitating multicentre and longi-
tudinal studies.
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Introduction
The measurement of perfusion has become an indispensable
tool in the clinical evaluation of the brain. A number of meth-
odologies can be applied for this purpose, each with its own
advantages and disadvantages [1].While dynamic susceptibil-
ity contrast (DSC)-magnetic resonance imaging (MRI), com-
puted tomography (CT) perfusion imaging, single-photon
emission tomography (SPECT), and H2[15O] positron-
emission tomography (PET) are well-established methods
for investigating blood flow in neurological diseases, arterial
spin labeling (ASL) MRI has emerged as a versatile comple-
ment that warrants regular consideration in the clinical setting.
SPECT, CT, PET, and DSC-MRI measure perfusion by
dynamic imaging of the passage of a contrast agent. By con-
trast, ASL generates an image by magnetically “labeling” wa-
ter molecules as an endogenous tracer as they travel to an
organ of interest. Selective radiofrequency (RF) irradiation
inverts the magnetisation of arterial blood water in the region
* M. Smits
marion.smits@erasmusmc.nl
1 UCL Institute of Neurology, Queen Square, London, UK
2 Stanford School of Medicine, Stanford, CA, USA
3 Medical Image Analysis and Biometry Laboratory, Rey Juan Carlos
University, Móstoles, Madrid, Spain
4 Neuroradiology, Department of Diagnostics and Pathology, Verona
University Hospital, Verona, Italy
5 Neuroradiology, Department of Radiology, Ghent University
Hospital, Ghent, Belgium
6 Department of Radiology, ErasmusMC—University Medical Centre
Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
Neuroradiology (2015) 57:1181–1202
DOI 10.1007/s00234-015-1571-z
or plane to which it is applied, usually in the neck for brain
perfusion, and a downstream measurement is taken as labeled
spins exchange into the tissue of interest [2]. In most ASL
methods, the resulting images are compared to control images
in which no inversion pulse is applied. The difference reveals
the perfusion, indirectly related to the quantification of cere-
bral blood flow (CBF) in well-characterised units of millilitres
of blood per 100 g of tissue per minute.
The physical basis of ASL offers its greatest advantage
over traditional contrast bolus techniques: it is non-invasive.
ASL does not require a gadolinium-based tracer, eliminating
risk of nephrogenic systemic fibrosis in patients with renal
dysfunction [3]. ASL is also favourable for paediatric popula-
tions, as it avoids the technical difficulties and ethical prob-
lems of contrast agents and radiation exposure with CT and
nuclear medicine techniques [4]. In addition, this makes the
method easily repeatable, a trait that is useful for performing
perfusion-based functional MRI (fMRI) and evaluating
changes over time [5]. Reproducibility has been addressed in
a number of studies, verifying the potential of ASL for longi-
tudinal monitoring of CBF changes [6–9].
The main drawback of ASL is the signal-to-noise ratio
(SNR), which is inherently low because inflowing labeled
molecules comprise only about 1 % of the static tissue signal
[10]. This increases the total necessary scan time, making the
technique particularly sensitive to motion artefact [11]. Flow
quantification can be complex, as the signal is dependent on a
number of physiological parameters. Sources of error include
transit time, inversion pulse profile, and labeled blood that
does not perfuse [12].
Publications about ASL in neurological diseases have in-
creased in recent years. Technological improvements in MRI
scanners and ASL methods are undeniable, and the popularity
of ASL in clinically relevant research is growing as non-
specialists become acquainted with commercially available
acquisition and analysis software. However, routine clinical
use of ASL is still limited to few centres [13]. Detre et al.
[14] find it ‘perplexing’ that the method has not been incor-
porated into routine clinical practice, while Golay and
Guenther [13] perceive a ‘lack of enthusiasm from the clinical
community’. Why is this? There are a number of potential
factors, such as the low SNR compared to other imaging mo-
dalities. ASL techniques can be complicated and have tradi-
tionally not been widely compatible with commercial scan-
ners. The utility and benefits of ASL are often eclipsed by the
greater prevalence of modalities such as DSC-MRI; some cli-
nicians may not request ASL as they are not accustomed to
non-invasive CBF quantification [14]. In addition to a lack of
awareness of the potential clinical utility of ASL, several other
issues can be identified that seem to impede widespread clin-
ical use. These include difficulties with image post-process-
ing, a wide variety of available acquisition techniques and
parameters, and a lack of guidelines for interpretation [15].
Communication may resolve some of these issues. The estab-
lishment of the ASL network has been a joint effort to rectify
the ASL information gap by providing a centralised commu-
nication platform [13]. The recently published white paper on
the clinical implementation of ASL [16] aims to reduce the
confus ion tha t comes wi th the many d i f f e r en t
implementations and provides clear guidelines for sequence
implementation.
In this review paper, we describe how to use ASL imaging
of the brain clinically, particularly for those neurological dis-
eases with ample evidence of ASL’s clinical value: cerebro-
vascular disease, dementia, and neuro-oncology. We also pro-
vide some technical background and recommendations on
how to optimally acquire ASL images in line with the white
paper [16]. We aim to provide the reader with clinically rele-
vant and practical information to confidently implement and
use ASL of the brain in their routine practice.
ASL technique and acquisition
ASL provides quantitative parametric images of tissue perfu-
sion. For that purpose, it uses the water in arterial blood as an
endogenous, freely diffusible contrast medium. The main
physiological parameter that is measured with ASL is CBF,
which determines the delivery rate of oxygen and nutrients to
the capillary bed and is expressed as the volume of blood per
volume of tissue per minute (ml 100 g−1 min−1).
Physical and physiological principles
ASL’s aim is the assessment of tissue perfusion rate, which is
very different from macrovascular blood flow. Tissue perfu-
sion, or the exchange of water and nutrients with the tissue,
happens along the entire length of the capillaries (Fig. 1). ASL
basically ‘follows’ blood water molecules from the arterial
compartment all the way to the tissue capillary bed, using
them as a free diffusible tracer. ASL is easily carried out by
the inversion or saturation of the magnetisation along the Z-
axis of blood water molecules in the feeding arteries. This part
of the ASL acquisition is called the labeling. Following the
labeling, time is allowed for the blood to travel to the tissue:
the so-called post-labeling delay (PLD) or inversion time for
certain ASL techniques. The delay is chosen such that images
are ideally acquired at the time of exchange of the water mol-
ecules with the tissue magnetisation (Fig. 2). Arterial blood
labeling is achieved by a combination of RF pulses and gra-
dients in order to invert the longitudinal magnetisation (T1) of
blood water protons.
After the PLD, the image acquisition phase starts to obtain
signal from those labeled protons coming from the feeding
arteries into the tissue. Different types of readout can be
employed. In order to differentiate the labeled magnetisation
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signal from the static tissue magnetisation signal, two images
are acquired: one with (labeled image, Fig. 2a) and one with-
out (control image, Fig. 2b) labeling. Subtraction of the la-
beled from the control images provides the perfusion-
weighted image.
Most ASL techniques aim to avoid signal coming either
from the flow in vessels or from static tissue, employing for
that purpose additional gradient and RF pulses. In addition,
numerous pulse sequences have been developed to maximise
SNR by reducing all confounding and potentially artefactual
signals. In particular, multiple cycles of control and labeled
images are acquired, leading to typically 4–6-min acquisition
times. The need to acquire multiple repetitions may however
lead to additional artefacts, such as those due to patient mo-
tion, and necessitate the use of additional strategies to obtain
usable ASL data either during acquisition or with post-
processing techniques.
Several physical and physiological parameters will affect
the quality of the ASL image and need to be understood prior
to choosing the most appropriate sequence and parameters.
Relevant factors include the labeling efficiency, arterial blood
T1 and relaxation times, the blood transport time through
vessels and tissue (depending on flow velocity), and finally
the so-called magnetisation transfer effects.
Arterial labeling efficiency is the first key aspect to a good
ASL acquisition. How effectively we invert the longitudinal
magnetisation directly affects the eventually acquired signal.
Efficiencies, designated with α, can range from 80 to 98 %
with currently available pulse sequences, which need to be
taken into account when quantifying CBF [2, 17–20].
Both blood transit time and T1 relaxation are in the order of
seconds, meaning that about two thirds of the label will have
decayed by the time the blood reaches the capillary bed. The
optimal PLD is thus almost invariably a compromise between
the arterial blood T1 and transit time. Arterial T1 and feeding
arteries transit times both need to be taken into account to get a
proper absolute quantification by physiological modelling
[21]. Ideally, the arterial blood relaxation time (T1Blood) is
measured on an individual basis. In the capillary bed, the
arterial blood water will exchange with the surrounding tissue.
The ratio of tissue water versus intravascular water in the brain
is in the order of 20:1, meaning that only a very small propor-
tion of the measured water signal is affected by the magnetic
label. When the labeled water enters the tissue, over 90–95 %
exchanges with the tissue water instantaneously. For this rea-
son, it is impossible to measure any labeled venous blood
flowing out of the tissue, due to the very short T1 relaxation
time compared with the equilibrium time (1–2 s versus 10–
15 min for a nominal CBF of 50 ml/min/100 g, respectively)
[22].
One of the major confounds when using ASL comes from
magnetisation transfer effects. The application of off-
resonance RF pulses to label the arterial blood proximal to
the tissue of interest will induce a reduction of MR signal that
mimics the signal decrease induced by the labeled blood water
exchange. This is due to the fact that protons in macromole-
cules have a very short T2 and thus a very broad frequency
spectrum. As such, the off-resonance RF pulses used in any
asymmetrical ASL sequence will inadvertently not only satu-
rate the arterial blood but also protons in these macromole-
cules. This saturation will then be transferred to tissue water
molecules reducing the MR signal [23].
Fig. 1 Capillary bed where water and nutrient exchange with the brain
parenchyma takes place
Fig. 2 Schematic of the three periods in any ASL sequence: (I) labeling/
control period, (II) post-labeling delay (PLD), to allow for the
magnetisation to reach and exchange with the tissue, and (III)) imaging
period, during which the images of the brain are acquired. a Labeling
acquisition. b Control acquisition. The difference between the two
acquisitions only lies in the type of radiofrequency pulse and gradient
applied during the first part of the sequence (yes or no labeling)
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Three main categories of ASL pulse sequences have been
developed, each aiming to take these factors into account with
variable success: continuous ASL (CASL), pseudocontinuous
ASL (pCASL), and pulsed ASL (PASL). PCASL is at present
the sequence of choice, due to its high labeling efficiency
combined with its ease of implementation and hardware spec-
ifications for clinical scanners [16].
The ASL pulse sequence
Labeling methods
The first labeling method was CASL and was introduced in
1992 [2, 24]. The simultaneous application of both a constant
RF pulse and gradient Gz prescribes a well-defined labeling
plane where inflowing blood is continuously labeled during 2–
4 s (labeling duration) (Figs. 2 and 3). Image acquisition occurs
downstream from the labeled blood, usually with a large field
of view covering the entire brain, after the PLD. CASL, how-
ever, is strongly affected by magnetisation transfer effects due
to the long RF pulse. Additionally, due to the continuous ap-
plication of a low amplitude RF labeling pulse, this sequence is
usually difficult to implement on clinical scanners.
PCASL deals with some of CASL’s disadvantages. In par-
ticular, pCASL avoids the need of additional hardware. Also,
specific absorption rate (SAR) deposition is lower than in
CASL. PCASL uses series of short RF and gradient pulses
instead of the long RF and gradient pulses employed in
CASL. This train of short pulses results in an inversion with
the same effect and efficiency as with CASL. One drawback
in pCASL is its sensitivity to resonance offset at the labeling
plane, which can cause it to shift. Additionally, some spin
phase shift between RF pulses can occur. Both effects can
potentially reduce the labeling efficiency. Such effects can
be however minimised by reducing the time gap between
the consecutive RF pulses or through post-processing.
In contrast to (p)CASL, in PASL a large slab is inverted
along feeding arteries during the very brief labeling phase
(Fig. 4). The labeled bolus size thus directly depends on the
slab size and not on the labeling duration such as in (p)CASL.
There are many different implementations of pulsed ASL se-
quences, each applying different strategies [25]. With PASL,
the labeling efficiency is high while SAR is lower than in
CASL or pCASL. This, however, comes at the cost of a lower
SNR, which is theoretically only 70 % of the maximal SNR
achievable using (p)CASL [21, 26–28].
Background suppression
The signal from static tissue fluctuates due to physiological
and thermal noise effects. This interacts with the signal de-
rived from ASL, thereby increasing the physiological noise in
the image. Therefore, after the labeling duration (Fig. 2), ad-
ditional RF pulses are applied to reduce the tissue signal [29].
Readout
The traditional readout scheme for ASL makes use of fast
imaging techniques. Until recently, echo planar imaging
(EPI) has been the preferred acquisition technique. However,
more advanced methods now provide alternative readouts,
such as 3D-gradient and spin echo (GRASE) [30]. This se-
quence has great advantages for ASL because it allows acqui-
sition of the entire volume of interest in a single shot, thereby
reducing the slice-dependent variation in perfusion signal due
to differences in acquisition delays that are inherent to 2D
multi-slice methods. 3D GRASE also has superior SNR com-
pared to 2D acquisitions. An alternative to 3D GRASE is 3D
rapid acquisition relaxation enhanced (RARE) combined with
a spiral readout trajectory [31]. This sequence oversamples
the centre of the k-space, thus providing shorter echo
times and superior SNR, but can introduce through-plane
blurring due to long readout times [32]. Such blurring can be
reduced by segmenting the acquisition of the 3D readout into
multiple acquisitions.
Fig. 3 Labeling slice prescription
(in blue) in sagittal and coronal
views for (p)CASL. Feeding
arteries are shown in purple
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How to acquire your ASL scan
The white paper recommends a pCASL labeling scheme,
combined with background suppression and a segmented 3D
readout. SNR will be better at high field, so 3 T is preferred,
especially in patient populations with slow or poor blood flow
[16]. At 1.5 T, ASL is feasible when blood flow is not too
compromised and in the paediatric population but will require
longer scanning times to obtain sufficient signal.
Phased array coils (eight or more channels) are recom-
mended to provide higher SNR especially in the cortex. These
coils also allow parallel imaging techniques and may thereby
accelerate the acquisition [33].
Field strength
ASL is a low SNR technique and as such benefits from any
increase in SNR possible. As the signal in MRI grows qua-
dratically with the field strength, while the noise only linearly,
the SNR is expected to grow theoretically linearly with the
field strength [34]. In addition to a general higher SNR, higher
field strengths provide longer blood T1 relaxation, leading to a
further increase in SNR, especially in cases of slow flow [35,
36]. The potential of ultrahigh field strength imaging (i.e., at
7 T or higher) is discussed below under ‘Emerging applica-
tions and techniques’.
ASL at high field, however, also comes with disadvan-
tages. First, not only T1 but also T2 will be affected by field
strength and will generally be much shorter at 3.0 than 1.5 T
[34], with a concomitant reduction in T2*. This will result in a
slight reduction of SNR due to the long readouts usually
employed in ASL (based on EPI or a combination of EPI with
multiple spin echoes such as 3DGRASE), during which some
of the available signal from the exchanged labeled blood will
have disappeared. This effect should be accounted for in the
quantification if one does not want to underestimate perfusion
at higher field strength [37]. Second, both the applied and
main magnetic fields will in principle be less homogenous at
3.0 than 1.5 T. Finally, the move to higher field strengths
comes with an increase in the RF deposition. Advanced
methods including optimised RF shimming have now been
developed to reduce hot spots in the applied RF field and are
available for all ASL protocols.
All in all, despite these disadvantages, 3.0 T has been shown
to be much better suited for ASL than 1.5 T, as the increase in
SNR overcomes most of the potential side effects of high field
strength scanners. This does not mean that 1.5 Tcannot be used
and can in fact be ideal for certain applications where a rela-
tively high perfusion is expected, such as in children between 2
and 18 years old [38] (Fig. 5), or in other organs, such as the
kidneys, for which the advantages of lower field (i.e., reduced
main and applied magnetic field inhomogeneities and reduced
RF deposition) will counterbalance the loss of SNR.
Acquisition parameters
For pCASL, the most important acquisition parameters to
choose are the labeling duration and the PLD.
The choice of PLD is highly dependent on the—pre-
sumed—blood velocity. The recommended PLD is 2,000 ms
in neonates, 1,500 ms in children, 1,800 ms in healthy adults
<70 years of age, and 2,000ms in healthy adult >70 year of age.
In adult patients, 2,000 ms is generally recommended, to allow
sufficient time for proper delivery of the blood to the tissue.
For spatial resolution, 3–4-mm in-plane and 4–8-mm
through-plane are recommended to achieve sufficient SNR.
In segmented acquisitions such as 3D RARE stack-of-spiral
or 3D GRASE, it is recommended to use 8 to 12 segments or
arms. If the readout is 2D EPI or spiral single shot, a minimum
echo time is desirable. Scan time for clinical purposes should
take no longer than 4–5 min, to minimise artefacts related to
motion. Further recommendations, also for PASL and CASL,
can be found in Alsop et al. [16].
Positioning
The labeling plane must be located in a region where the
relevant feeding arteries are relatively straight and
Fig. 4 Labeling slice prescription
(in blue) in sagittal and coronal
views for PASL. Feeding arteries
are shown in purple
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perpendicular to the labeling plane. Figure 6 shows examples
of both bad and good positioning of the labeling plane. Prior to
positioning, an MR angiogram may be acquired such that the
feeding vessels are visualised. A quick, low-resolution angio-
gram is sufficient for this purpose. Alternatively, other land-
marks can be used. The labeling plane can be placed approx-
imately 8–9 cm inferior to the anterior–posterior commissure
line in adults or approximately 1 cm below the inferior border
of the cerebellum. A caveat with positioning the labeling plane
like this is that the lower cerebellar sections may suffer from
artefacts due to direct saturation from the RF pulses.
It is extremely important that the labeling plane does not
include any sources of susceptibility effects such as air or bone
close to the orbitofrontal or temporal areas but also dental
fillings or metallic surgical material. These sources of suscep-
tibility can ruin the labeling and may result in a lack of signal
in the vascular territory of the vessel in which labeling failed
(Fig. 7).
Motion
Due to the fact that perfusion-weighted imaging with ASL is a
subtraction technique, combined with the necessity of many
‘control-label’ repetitions, ASL is highly sensitive to motion.
Background suppression substantially reduces motion arte-
facts. Remaining motion artefacts can be further reduced by
using image registration post-processing techniques similar to
those used in functional MRI.
Clinical applications
Perfusion patterns in various neurological diseases differ be-
cause they reflect different mechanisms. Although it is useful
to group incidences of hyperperfusion and hypoperfusion in
large-scale analysis of ASL findings [39, 40], one needs to
keep in mind that such outcomes can be indicative of a num-
ber of pathologies. ASL depicts physiology. Stroke and is-
chaemia yield hypoperfusion because they result from disrup-
tions of brain haemodynamics. In contrast, regional hypoper-
fusion patterns in neurodegenerative diseases likely reflect a
progressive breakdown of synaptic pathways. Hyperperfusion
in brain tumours is a result of greater metabolic needs of un-
controlled cell replication, whereas ictal hyperperfusion re-
cruits metabolites for uncontrolled electrical discharges.
Fig. 5 Cerebral blood flow at different ages, for grey matter, white
matter, and their ratio. Reprinted with permission from [37]
Fig. 6 Incorrect (left) and correct
(right) positioning of the labeling
plane. The labeling plane needs to
be placed perpendicular to the
feeding arteries and sources of
susceptibility artefact (such as air
in the sinuses) should be avoided
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Cerebrovascular disease
The measurement of perfusion is probably most directly ap-
plicable to cerebrovascular disease and ischaemic episodes.
These conditions typically manifest themselves on ASL as
regions of altered perfusion or delayed arterial transit time
(ATT) because malformed, occluded, and damaged vessels
perfuse less labeled water than normal vessels [41]. ASL has
been explored for the non-invasive detection of cerebrovascu-
lar abnormalities, identification of ischemic events, and risk
assessment. The technique can be combined with an acetazol-
amide challenge to assess the cerebrovascular reserve [42, 43].
The development of selective ASL, which can visualise the
vascular territory of a single vessel, is particularly applicable
to these investigations [44].
The physiological basis of ASL may however pose diffi-
culties in patients with suspected cerebrovascular disease.
Qualitative assessment of cerebral blood flow maps can be
clinically useful but may be insufficient and inaccurate in the
presence of globally reduced cerebral blood flow, such as in
patients with bilateral carotid disease or reduced cardiac out-
put. ATT is well-defined for healthy vasculature but can vary
greatly in disease states, possibly making conventional ASL
techniques with a single PLD unsuitable [45]. Slow flow is
more difficult to quantify than high flow [46]. Observed var-
iability in ATT for chronic stroke patients, for example, indi-
cates that individual transit delay times ought to be established
in cases of compromised cerebral vasculature before
collecting CBF data [47]. Recent work demonstrated a
multi-PLD technique that measures both CBF and ATT, cre-
ating parametric maps of regional ATT to better model path-
ological tissue [48, 49]. The technique was recently validated
against gold standard H2[15O]-PET measurements [43] and
DSC [50] in instances of steno-occlusive disease.
Vascular disease
ASL is useful for identifying abnormal cerebral perfusion
caused by stenosis or constriction of blood vessels. ICA oc-
clusion [51, 52] and stenosis [53] have been identified with
ASL by delayed ATT in the hemisphere ipsilateral to the af-
fected vessel, findings that are validated by correlation with
SPECT [54]. In addition, surgical correction by carotid artery
stenting has been quantified with pCASL [55]. In Moyamoya
disease (MMD), the extent of collateral perfusion, which is
one of the surrogate markers of disease severity and stroke
risk, can be assessed with ASL. Measurements reportedly
agree with those of gold standard techniques [56]. Most re-
cently, Donahue et al. [57] correlated ASL and BOLD mea-
surements of haemodynamics with digital subtraction angiog-
raphy (DSA) arterial circulation time, an established marker of
disease severity, determining that the non-invasive MRI
methods provide complementary tissue-level information
about parenchymal reserves. ASL measurements of CBF for
MMD have been correlated with SPECT [58], as well as
H2[15O]-PET in young adults [59]. Clinical trials evaluating
the predictive value of ASL for identifying high-risk MMD
patients are warranted. Early identification of at-risk brain
tissue in cases of neurotuberculosis [60] and Hashimoto’s en-
cephalopathy [61]—the latter a case study in which only
CASL detected abnormal hyperperfusion—support the inclu-
sion of ASL in investigative imaging protocols.
Arteriovenous malformation (AVM) has an associated
‘steal phenomenon’ that has been visualised with PASL
[62]. PASL was also shown to be useful in measuring
the amount of shunt reduction achieved after embolisa-
tion of AVMs [63], as well as confirming obliteration of
AVM after stereotactic radiosurgery [64, 65]. Vessel-
encoded pCASL was found to be as good as DSA at
Fig. 7 Labeling failure in the left
internal carotid artery. There is
absence of signal on the ASL
perfusion-weighted images (PWI)
and corresponding cerebral blood
flow (CBF) maps in the arterial
territory of the left internal carotid
artery. Note the large
susceptibility artefact in the area
of the left internal carotid area on
the T2* weighted (T2*w) image,
as the likely cause of the labeling
failure. Diffusion weighted
imaging (DWI) is normal,
supporting interpretation of this
finding as an artefact
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identifying AVM feeding vessels and their contribution
fractions [66].
In addition to verifying surgery outcomes, the ease of re-
peat ASL measurements of time-dependent CBF changes
could be useful in post-treatment monitoring. Serial ASL
can track the status of patients at risk of angiographic vaso-
spasm in the days following subarachnoid haemorrhage [67].
Selective ASL is useful inmonitoring haemodynamic changes
and potential risk of cerebral hyperperfusion after
revascularisation surgery for MMD [68, 69]. Similarly, serial
PASL upon insertion of transjugular intrahepatic
portosystemic shunts in cirrhotic patients could help predict
hepatic encephalopathy [70].
(Sub)acute ischaemia
Ischaemia is identifiable by regions of altered perfusion due to
anoxic damage. ASL has been used to measure global hypo-
perfusion in individuals in a minimally conscious state due to
traumatic brain injury, stroke, or hypoxic-ischemic encepha-
lopathy, and repeated measurements can be useful for tracking
clinical improvement [71]. ASL has also been used to identify
CBF deficits—some located in anatomically apparently intact
regions—in chronic stroke survivors, a finding that may have
major implications for the study of stroke-related behavioural
deficits [47]. Conversely, regions of hyperperfusion have been
seen in patients with a history of ischemic injury, potentially
due to loss of autoregulation of cerebral vascular resistance
[72]. ASL has also been used for investigations of stroke-like
episodes in patients with mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS), identifying
hyperperfusion in the acute phase and hypoperfusion in the
chronic phase [73].
Identification of transient ischemic attack (TIA) is essential
for optimal patient outcome, as urgent specialised manage-
ment may reduce the risk of subsequent stroke by 80 %
[74], but accuracy of this diagnosis is often difficult. Diffusion
weighted imaging (DWI) is usually recommended for evalu-
ation of suspected TIA, but commercially available pCASL
software can now increase the diagnostic yield of MRI [75].
Recently, Zaharchuk et al. [76] reported that pCASLwasmore
sensitive to abnormalities in TIA patients than DWI and MR
angiography and nearly as sensitive as DSC in identifying
TIA lesions. When performed within 24 h, pCASL demon-
strated perfusion abnormalities in TIA patients with otherwise
normal imaging [77]. Ultimately, pCASL may bolster confi-
dence of diagnosis in post-TIAworkup.
For the moment, it has to be said that ASL has a reserve
role in the evaluation of (sub)acute ischemic stroke compared
to DSC, advantageous only when gadolinium contrast agents
are contraindicated. ASL can confirm the presence of regional
hypoperfusion—thus ruling out stroke mimics—and rapid
identification of the penumbra. Regions with reduced CBF
measurements post-stroke have been shown to be largely con-
sistent with regions of DSC hypoperfusion, and one study
reported that areas of hyperaemia were more conspicuous on
pCASL perfusion-weighted images [78]. This may require
further validation, as another group recently found that
periprocedural DSC was more sensitive to regional CBF
changes after invasive recanalisation [79]. Bokkers et al.
[80] found high agreement between pCASL and DSC find-
ings during initial evaluation for stroke. However, ASL may
not detect small perfusion deficits as accurately as larger def-
icits, and utility for acute stroke may be limited to the pCASL
sequence: Zaharchuk et al. [81] found that CASL did not
always agree with a DWI perfusion-diffusion mismatch para-
digm at 1.5-T scanners. Potential benefits of ASL in diagnos-
ing and classifying infarcts include the detection of border
zone and cortical lesions [82], and general identification of
infarct zone is supported in other studies [83, 84], but the
correct definition of penumbra is not fully established [85].
Utility of ASL in evaluating damage and recovery of arte-
rial ischemic stroke has also been demonstrated in paediatric
populations [86]. Perinatal and neonatal ischaemic strokes
have relatively unclear mechanisms and few treatment op-
tions; a recent study employed ASL in attempts to elucidate
brain haemodynamics, demonstrating its feasibility in new-
borns and supporting its inclusion in MRI protocols [87]. Fur-
thermore, Pienaar et al. [88] produced a quantitative measure
to associate regional hyperperfusion with decreased DWI dif-
fusion upon neonatal ischemic insult.
Chronic ischaemia and cerebrovascular reserve
While ASL in the context of (sub)acute ischaemia has proba-
bly only limited value, its role in assessing risks and conse-
quences of chronic cerebrovascular disease is supported by
the published literature. In particular, ASL can be used to
assess the cerebrovascular reserve and the hypoperfusion syn-
drome. The cerebrovascular reserve capacity (CRC) describes
to what extent cerebral perfusion is able to increase in the
context of vasodilatatory challenges, such as with CO2 inha-
lation or acetazolamide injection. In patients with chronic ce-
rebral hypoperfusion, this reserve is limited due to the fact that
the vascular bed is already dilated at baseline, and its capacity
to dilate due to vasodilatory challenge is exhausted. While at
present the CRC is not taken into account to set the indication
for carotid artery surgery [89, 90], recent studies indicate that
the risk of cerebral infarction in patients with carotid artery
stenosis is considerably higher with reduced CRC [91]. CRC
assessment can furthermore contribute to risk assessment prior
to carotid artery and heart surgery.
ASL is well suited to assess the CRC because measure-
ments can be repeated, are non-invasive, and are quantitative.
Exogenous contrast-enhanced techniques, as well as being
invasive, suffer from circulating contrast medium for several
1188 Neuroradiology (2015) 57:1181–1202
days, precluding repeated measurements within this time
frame.
ASL has been combined with acetazolamide challenge to
assess cerebrovascular reactivity [42, 43], allowing for identi-
fication of tissue at highest risk for possible stroke [92]. A
recent study related ASL measurements to BOLD activity
upon acetazolamide challenge, indicating that CBF measure-
ments contain crucial information not identified with BOLD
alone [93].
The effects of treatment can be assessed with ASL. For
instance, a study comparing the results of carotid angioplasty
with stent placement to those of carotid endarterectomy illus-
trated restoration of collateral blood flow distribution and nor-
malisation of regional CBF [94].
White matter lesions (WML) are one hallmark of small
vessel disease yet are also seen in neuroinflammation, gliosis,
and other neurodegenerative processes [95, 96]. While it is
currently unclear if ASL perfusion quantification can distin-
guish between WML types, one study reported correlation
between perfusion disturbances and the extent of white matter
disease, with later-stage WML subjects exhibiting decreased
CBF in both white and grey matter [97]. Sensitivity of ASL is
reduced in white matter, due to lower CBF and longer ATT
than grey matter, but recent methodological advances includ-
ing higher field strength, pCASL, and sequence optimisation
can address that challenge [98, 99].
Clinical assessment and interpretation
The diagnosis of ischaemia on ASL is generally based on
reduced flow from the proximal routes. Blood flow via
collateral routes is difficult to detect as it takes longer,
leading to increased delays between the labeling of the
spins and their arrival in the imaged voxel. The main
problem of ASL in studying acute or chronic cerebral
and cardiovascular conditions is related to transit delay
and visualisation of collateral flow due to the rapid decay
of the magnetic label [5, 100]. Choosing the appropriate
PLD for ASL is therefore crucial but as mentioned above
is a trade-off against SNR [101].
When the arterial arrival times are the same as or longer
than the PLD, labeled spins can be visualised in the arteries
feeding the ischemic tissue, a finding that has been called the
arterial transit artefact (ATA) [42]. Recently, Yoo et al. report-
ed high utility of bright vessel appearance due to ATA on
pCASL imaging for localising occlusions in acute stroke
[102]. This artefact, which in this context is thus in fact an
important marker of pathology, is however not visible if a
vascular suppression method is applied. Vascular suppression
methods have their use when ATA needs to be avoided for
optimal CBF quantification [103] but should not be used
when ASL is performed for the detection of ischaemia. Low
ASL signal, with surrounding cortical areas of high signal
intensity due to ATA in the border zones of the middle
(MCA) and anterior cerebral artery (ACA) or MCA and pos-
terior cerebral artery (PCA), has been called the ‘border zone
sign’. This sign was found to be more sensitive than contrast-
enhanced perfusion-weighted imaging for identifying subtle
perfusion anomalies [104]. ATA has been correlated with im-
proved outcome after acute stroke [83], possibly reflecting the
presence of collateral flow [105] (Fig. 8). ATAwas often pres-
ent surrounding the ischemic core and tended to be associated
with lack of progression to infarct and better clinical outcome
[86]. One should keep in mind however that ASL tends to
overestimate the perfusion deficit and penumbra, especially
in patients with small infarct size [106].
ASL images are very sensitive to alterations or physiolog-
ical variants of the brain drainage and circulation (circle of
Willis normal variants and developmental venous anomalies),
and they can be used to detect AVMs (Fig. 9) or fistulas
(AVF), quantify the arteriovenous shunting, and evaluate
CBF alteration in the adjacent and distant brain tissue [107].
If a significant asymmetry of brain perfusion is detected on the
ASL or CBF maps, it is important to review all the standard
MR sequences acquired and to add MR angiography to eval-
uate or exclude the presence of possible normal variants or of
pathologic vascular shunts which can cause the alteration of
the brain perfusion.
Dementia
Diagnosis and evaluation of neurodegenerative disease is a
rapidly expanding application of ASL, particularly with recent
growth in biomarker exploration for Alzheimer’s disease
(AD) and dementia [108]. Not only does the quantification
of perfusion offer a role in monitoring disease progression,
which is potentially useful for clinical trials of new therapies,
it may also be able to provide helpful diagnostic information if
characteristic perfusion patterns can be established. Changes
in brain metabolism and perfusion often precede observable
structural changes such as atrophy in neurodegenerative dis-
eases. This is most commonly assessed with fluor-
deoxyglucose (FDG)-PET, which is not always cost-
effective [109] and has limited availability, in contrast to
ASL, which can be added to the routine structural MRI exam-
ination at low incremental cost and only 5 min of additional
scan time. CBF measurements derived from ASL correlate
with gold standard H2[15O]-PET [110, 111].
AD is the most common cause of dementia [108]. The use
of ASL in AD was recently reviewed [112], assessing the
technique as an emerging biomarker. Altered metabolic activ-
ity measured with FDG-PET has been linked to early patho-
logic changes in AD patients in multiple studies, and regions
of altered perfusion measured with ASL appear to overlap
with these findings [113, 114]. A number of studies have
yielded interesting perfusion comparisons between patients
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with various forms of dementia and demographically matched
healthy controls. ASL has detected global perfusion decreases
in AD patients [115] in addition to regional hypoperfusion.
Both AD and mild cognitive impairment (MCI), the interme-
diate stage between normal cognitive decline and dementia,
have been associated with hypoperfusion in the middle occip-
ital areas, medial temporal lobe, and especially the parietal
lobe [116]. Similar hypoperfusion has been reported in the
posterior cingulate and precuneus in addition to certain frontal
and parietal regions [117, 118]. Frontotemporal dementia is
also associated with regional hypoperfusion, though the spa-
tial distribution is different from that of AD [119], with bilat-
eral hypoperfusion in the frontal cortex and insula and hyper-
perfusion in the precuneus and posterior cingulate. ASL is
potentially a useful tool for this important differential diagno-
sis [120, 121].
Regional hypoperfusion as assessed with ASL may be a
good predictor of cognitive decline in AD and potentially
Fig. 8 Acute ischaemia in the left
occipital lobe, with diffusion
restriction on the diffusion-
weighted image (DWI) and
apparent diffusion coefficient
(ADC) map, and high signal
intensity on the T2 weighted
(T2w) images. The colour-coded
cerebral blood flow (CBF) map
shows hypoperfusion in the
ischaemic region, with the arrow
indicating the residual vascular
signal in the arteries feeding the
ischaemic tissue (arterial transfer
artefact: ATA)
Fig. 9 Post-contrast T1 weighted
(T1w: top row) and perfusion-
weighted images (PWI: bottom
row) obtained with ASL of an
arteriovenous malformation as
evidenced by digital subtraction
angiography (right column:
DSA). The arrows indicate high
signal in the draining veins
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identify candidates for treatment trials [122]. Regional reduc-
tions in CBF have also been correlated with known AD risk
factors like the apolipoprotein E epsilon 4 allele, further
supporting ASL’s utility in indicating disease progression
from MCI to AD [123]. Findings from Dashjamts et al. sug-
gest that ASL imaging is better than morphological imaging
(voxel-based grey matter density) in the diagnosis of AD
[124], although Bron et al. report no added diagnostic value
of ASL over structural MRI atrophy markers in presenile de-
mentia classification [125]. A number of studies utilise ASL
as part of a multi-tool approach for elucidating AD-related
changes, for instance alongside magnetic resonance spectros-
copy [126] or hippocampal volume measurement [127]. Re-
gional reduction of perfusion in AD is not necessarily related
to other instances of neuropathological hypoperfusion. Pro-
posed mechanisms for AD and subcortical ischaemic vascular
dementia remain controversial [128], with debate as to wheth-
er hypoperfusion is a cause or consequence of neurodegener-
ation [115]. Yoshiura et al. found no correlation between re-
gional ATT prolongation and regional hypoperfusion in AD
[129], which suggests a different mechanism than that of ce-
rebrovascular disease.While co-occurring pathologies make it
difficult for researchers to agree, vascular abnormalities have
recently been suggested to play a critical role in AD pathology
given known characteristics of beta-amyloid clearance dys-
function [130].
As biomarker research has greatly expanded over the last
two decades, reconciliation of the accumulating findings
comes with many considerations [108], particularly the trans-
lation of group-level findings to individual patients [131].
Overall, the literature demonstrates both the technical feasibil-
ity and advantages of ASL in neurodegenerative disease. Ev-
idence suggests that AD staging models ought to incorporate
CBF changes as an early biomarker [132]. The relative low
cost and ease of implementation of ASL favour its potential
inclusion inmethods for long-term surveillance of ageing pop-
ulations. Wang et al. demonstrated the feasibility and compel-
ling clinical utility of ASL across multiple sites [133].
Clinical assessment and interpretation
For the diagnosis of AD, the two regions to scrutinise for
hypoperfusion are the precuneus and the posterior cingu-
late cortex [111, 112, 120, 122, 129, 134–137]. In addi-
tion, hypoperfusion in the lateral parietal cortex bilaterally
supports the diagnosis [135, 137, 138]. This is essentially
not different from the findings with FDG-PET, with which
these regions are identified as being hypometabolic. Sim-
ilar abnormalities, albeit to a lesser extent, can be found in
MCI [135, 139, 140]. Note, however, that hyperperfusion
can also be observed in MCI, particularly in the hippo-
campus, amygdala, and striatum [139].
An important pitfall in the diagnostic assessment of ASL-
perfusion maps for AD and MCI is the fact that the precuneus
and posterior cingulate cortex are more highly perfused than
the rest of the cerebral cortex [141] (Fig. 10). Mild hypoperfu-
sion thus may not be immediately apparent upon qualitative,
visual inspection, as it will not appear as a cortical perfusion
deficit. Rather, when perfusion in these regions approaches that
of the rest of the cerebral cortex, and is not clearly higher, this
should be considered as hypoperfusion and indicative of neu-
rodegenerative pathology (Fig. 11). Clearly, quantitative as-
sessment will be beneficial in detecting such subtle perfusion
abnormalities, but unfortunately the lack of reference stan-
dards, large inter- and intra-individual variation, and issues
with quantification prohibit such an evaluation at the moment.
Neuro-oncology
Perfusion imaging provides useful information about vascu-
larisation and vascular proliferation, which is directly applica-
ble to the assessment of brain tumours. Tumour growth re-
quires a substantial supply of blood. Angiogenesis occurs
once neoplastic tissue reaches a critical mass, and the particu-
lar function and architecture of new blood vessels are linked to
tumour type [142]. While relative cerebral blood volume
(CBV) measured by DSC perfusion MR imaging is the most
common measurement, CBF measured by ASL perfusion im-
aging has comparable utility in tumour diagnosis, grading, and
follow-up of tumours and treatment.
While it may not be appropriate to compare perfusion
values determined with different techniques [142], multiple
studies seem to indicate that DSC and ASL findings correlate
well. Although DSC perfusion is more widely used to evaluate
brain tumours, Lehmann et al. [143] found that pCASL detect-
ed gliomas, metastases, and meningiomas on a 3 T scanner as
accurately as DSC, and Järnum et al. [144] reported a similar
correlation for a variety of tumour classifications. More recent-
ly, Hirai et al. [145] found that ASL measurements nearly
Fig. 10 Colour-coded cerebral blood flow maps acquired with ASL
overlaid on structural T1w images show hypoperfusion in the
precuneus and posterior cingulate cortex (arrowheads) and posterior
parietal cortex (arrows) bilaterally consistent with Alzheimer’s disease
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matched DSC quantifications of regional CBF in gliomas, and
van Westen et al. [146] reported ASL and DSC blood volume
correlation for various intracranial tumours.
Pretreatment classification of tumour types can be hugely
important for timely and effective intervention. A recent study
found that ASL performed as well as DWI and FDG-PET in
distinguishing primary central nervous system lymphomas
(PCNSLs) from glioblastoma, identifying the denser and less
vascular PCNSLs due to decreased perfusion [147]. This ex-
ample demonstrates the strategy for using ASL to differentiate
tumour types: correlating known histological characteristics
with perfusion measurements to yield information otherwise
collected by more invasive means. A number of other studies
have illustrated this approach. Noguchi et al. [148] found sta-
tistically significant differences in ASL-quantified tumour
perfusion when comparing haemangioblastomas to gliomas,
meningiomas, and schwannomas due to the tumour types’
different vascular densities. Three-tesla PASL has been used
to differentiate haemangioblastomas and metastatic tumours,
which are the major differential diagnoses of tumours in the
posterior fossa in adults [149]. Recently, PASL showed high
accuracy in distinguishing pilomyxoid astrocytomas (a rela-
tively newWHOClassification addition) from pilocytic astro-
cytomas [150]. This type of differentiation is essential for
making therapeutic decisions.
Tumour grading is another important informant of treat-
ment and is partly determined by the extent of vascular pro-
liferation. High- and low-grade gliomas can be distinguished
on the basis of perfusion quantification with CASL [151, 152]
and PASL [153–156]. Relative CBF measured with ASL has
been shown to correlate with relative CBV measured with
DSC [157]. Generally, high-grade tumours exhibit CBF above
the individual mean, while low-grade tumours exhibit CBF
below the mean [153].
Follow-up of tumours with perfusion imaging can greatly
inform management. Adult low-grade tumours undergo ma-
lignant transformation, which is characterised by a switch
from avascular to vascular tumour, known as the angiogenic
switch. This is yet to be measured with ASL. Perfusion in
high-grade tumours can be measured with ASL before and
after treatment to assess response and progression. This is
useful in the context of anti-angiogenic treatment: in a case
report of a patient treated for recurrent glioblastoma, ASL
illustrated tumour progression before conventional MRI did
[158]. ASL was furthermore reported to be more effective
than DSC at distinguishing radiotherapy-induced necrosis
from high-grade glioma recurrence (sensitivity >90 %) [159].
Clinical assessment and interpretation
ASL is not yet commonly used for brain tumour assessment
and diagnosis, presumably due to the fact that contrast is gen-
erally administered for this indication. ASL as a non-invasive
technique is thus often dismissed as irrelevant, but this may not
always be justified. Particularly in the paediatric population,
patients after chemotherapy with difficult intravenous access,
and cases of renal insufficiency, a non-invasive techniquewith-
out exogenous contrast administration may be preferred. A
clear advantage of ASL is that CBF quantification is not af-
fected by T1 and T2 leakage effects with blood–brain barrier
disruption, which is a major issue with contrast-enhanced per-
fusion techniques. Furthermore, depending on the readout se-
quence used, susceptibility artefacts are not necessarily an is-
sue with ASL. The assessment of CBF in brain tumours is not
different from contrast-enhanced perfusion techniques, al-
though quantitative thresholds are not yet widely established.
Considerations and limitations
Quality control
As with any imaging exam, quality control is essential prior to
clinical assessment. Common artefacts include motion, signal
Fig. 11 Early perfusion changes in Alzheimer’s disease (AD). Top row:
colour-coded cerebral blood flow (CBF) maps acquired with ASL
overlaid on structural T1w images at baseline; bottom row: coronal
reconstructions at the level of the hippocampus at baseline and after
3 years. At baseline, hippocampal volume is normal, but hypoperfusion
in the posterior cingulate cortex/precuneus (arrows) already indicates
AD. Note that the hypoperfusion may easily be missed, as there is no
clear perfusion deficit. Perfusion in this area however should be much
higher than the rest of the cortex, while here it is similar to the rest of the
cortex. This is abnormal. After 3 years, structural changes consistent with
AD, i.e., hippocampal and global atrophy, also become visible
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dropout, distortion, bright spots, and labeling failure [160].
Motion artefacts may appear as rings or curved lines and
may result in artefactually high or low CBF values (Fig. 12).
Signal dropout and distortion result from susceptibility effects
with EPI-based readout sequences. These typically occur at
air–tissue interfaces, such as near the frontal sinuses or mas-
toid bone. Metallic surgical material and haemorrhage are ad-
ditional sources of such artefacts. Bright spots are random—
clusters of—voxels of very high perfusion, due to residual
vascular signal. As described above, note that this artefact is
in fact of diagnostic value as a feature of slow flow in acute
ischaemic stroke. Failure to label the inflowing blood, e.g. due
to local susceptibility artefacts, results in apparent lack of per-
fusion in the entire affected vascular territory (Fig. 7). Finally,
ASL should never be acquired after the administration of
gadolinium-based contrast, as the resulting T1-shortening is
detrimental for the label (Fig. 13). Note that this effect is
noticeable for days after contrast administration.
Confounds
Brain perfusion is highly dynamic and will be influenced by
many factors [161]. Some factors are likely to generate long-
lasting global and local perfusion adaptations. These include
genetics, cognitive capacity [162], personality traits [163],
physical exercise [164], and age [165]. Other factors are much
more variable and define a state of mind at the time of exam-
ination. These include for instance mood [166], blood gases
[167], nutrition [168], stress [169], and medication use. Some
of the induced changes are global and related to vascular to-
nus, while other local variations are the results of psychotropic
effects on the brain. For the interpretation of perfusion maps
and derived values, such variance should ideally be taken into
account. Some changes induced by physiology, state of mind,
and non-metabolism-related factors may confound interpreta-
tion related to disease states, because such changes are in the
same areas and of a comparable magnitude. Especially early
abnormalities might be obscured by the noise introduced by
confounds and modifiers of perfusion. It is therefore sug-
gested that studies of perfusion of the brain always inquire
about possible confounds and modifiers using a questionnaire.
This information can then be used to understand the validity of
perfusion alterations. Where possible, corrections can be ap-
plied to the quantitative results bymeasuring the modifier, e.g.
blood gases and haematocrit. The use of a standard operating
procedure while performing the perfusion measurement is al-
so advisable to reduce the influence of, e.g. time of day, wake-
fulness/consciousness, satiety, acute substance use, and the
use of certain prescription drugs. As an example, drinking a
cup of coffee or smoking a cigarette just before the perfusion
measurement has substantial influence on both global and
local quantification [170, 171].
Paediatric population
As previously mentioned, ASL is particularly effective for
imaging paediatric populations. Non-invasive imaging avoids
ethical controversy over the injection of contrast agents, and
children have a higher baseline CBF signal, which results in a
better signal-to-noise ratio [4]. Repeat measurements, the ac-
curacy of which has been experimentally demonstrated, are
useful in neurodevelopmental studies of children [172] and
sustained monitoring in high-risk neonates, particularly in at-
tempts to identify factors linked to brain injury in develop-
ment [173]. Though applications of ASL in epilepsy, neo-
plasms, and other neurological disorders have not been fully
evaluated for paediatric groups, the same principles apply.
Studies have demonstrated the utility of ASL in evaluating
perfusion changes associated with sickle cell disease, the most
common cause of stroke in children [174]. However, care
must be taken to not overestimate CBF abnormalities. Since
most ASL studies are done in adult populations, sequences
must sometimes be optimised for a younger population with
different average physiological parameters [175].
Quantification
ASL’s ability to quantify CBF is its major advantage over
contrast-enhanced MR perfusion techniques. Quantitative as-
sessment of CBF potentially allows for the use of threshold or
reference values, thus aiding in the—more objective—differ-
entiation between healthy and diseased conditions. Such an
Fig. 12 Colour-coded CBF map
(a) with severe motion artefacts.
The artefacts can easily be
appreciated on the source images
(b, c) as linear and spiral patterns
Neuroradiology (2015) 57:1181–1202 1193
assessment is less user- and experience-dependent and more
sensitive to subtle alterations than visual assessment.
CBF is commonly quantified according to the following
equation for (p)CASL [21]:
CBF ¼
6; 000⋅λ⋅ M c−M lð Þ⋅ PLDeT1Blood
2⋅α⋅T1Blood⋅MPD 1−e
τ
T1Blood
  !
where λ is the brain/blood partition coefficient in millilitres
per gram, α is the labeling efficiency,Mc is the control andMl
is the labeled signal intensity, and MPD is the signal intensity
of a proton density-weighted image. This is used to normalise
the overall signal intensity which potentially varies due to
several confounders, such as hardware and patient variability
globally affecting the signal. Recommendations on how to
obtain MPD can be found in Alsop et al. [16]. Six thousand
is a conversion factor of the units fromml/g/s to ml/100 g/min.
While many of the parameters can be estimated, it is common
to use nominal values indicating that quantification is still
partially based on assumptions. Nominal values are as fol-
lows: λ=0.9 ml/g [176], T1Blood=1,650 ms at 3.0 T [177]
and 1,350 ms at 1.5 T [178], α=0.85 for pCASL [179], and
0.98 for PASL [180].
An important aspect affecting the quantitative assess-
ment of CBF is the partial volume effect, related to the
fact that the voxel size of ASL is several times that of 3D
T1-weighted acquisitions (Fig. 14). Hence, most voxels
contain a combination of tissues and/or cerebrospinal flu-
id. Different tissues have substantially different perfusion
characteristics. Perfusion in the white matter is about half
that of grey matter, while at the same time T1 is shorter
and arterial arrival time is longer. The partial volume ef-
fect becomes even more relevant in the presence of atro-
phy, when voxels contain relatively less grey matter and
subsequently lower average CBF. Such unwanted effects
are dealt with by using a post-processing technique called
partial volume correction [181].
Emerging applications and techniques
For the neurological diseases discussed above, current state-
of-the-art pCASL imaging is ready for clinical implementa-
tion. There are several more applications in which perfusion
imaging with ASL has potential value, but these are still more
or less in the phase of assessment. These include neurodegen-
erative diseases such as Parkinson’s [182, 183] and
Huntington’s disease [184, 185], multiple sclerosis
[186–188], epilepsy, and psychiatric disease. Below we high-
light the latter two.
Regarding the technical developments related to ASL,
we already touched upon the value and issues of imaging
at high field strength. Ultrahigh field strength (7 T or
higher) makes long PLDs (as long as 6 s) feasible, thereby
drastically improving ASL’s ability to visualise regions
with delayed flow and collateral blood flow [35, 189].
This also opens up the possibility of more accurate CBF
measurement in areas of relatively low perfusion such as
the white matter and arterial border zones. Quantification
of CBF is further improved at high field strength by the
reduction of partial volume effects with improved spatial
resolution [190]. SNR increases approximately fourfold
from 3 to 7 T [191]. High SNR in turn allows imaging
at increased spatial resolution (1–2-mm2 in-plane resolu-
tion) [191]. Imaging at multiple PLDs, effectively map-
ping and quantifying arrival times into the tissue [51, 192,
193], again is an area in which ultrahigh field strengths
will be beneficial, because this technique is currently lim-
ited by low SNR, persistent inaccuracies in regions with
severely delayed flow, and challenges with non-linear
fitting of CBF to the kinetic models [21].
A further technical development that we describe here is
territorial ASL, which has great potential for the functional
assessment of cerebrovascular disease.
While research studies in both these emerging applications
and techniques are interesting and show promising results,
proper clinical evaluation is still needed for assessing their
true value and validity, and further research is warranted.
Fig. 13 ASL acquisition—
inadvertently—after contrast
administration (a). While the
post-processing software will
provide a ‘CBF’ map (b), the
source images (c) clearly show
random noise without any signal
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Epilepsy
In the evaluation of epilepsy, SPECT and PET are used to
measure ictal and interictal blood flow for localisation of ep-
ileptogenic activity, illustrating increased perfusion in the crit-
ical period and decreased perfusion after seizures [194]. How-
ever, nuclear medicine techniques can be expensive or contra-
indicated. ASL can potentially assist clinical diagnosis by
quickly identifying potential perfusion asymmetries or ruling
out causes such as stroke. Non-invasive measurements could
be repeated to assess changes over time, particularly in re-
sponse to treatment. Repeated seizures can lead to a chronic
epileptic condition, demonstrated experimentally [195] and
clinically [196], and it is thought that neuroinflammation
and seizure-induced vascular alterations contribute to
epileptogenesis [197], warranting investigation of such chang-
es with perfusion imaging.
A few studies have employed interictal [198–200] and im-
mediate post-ictal [201, 202] PASL measurements in cases of
partial epilepsy. Correlation between ASL, PET, and electro-
physiological data has been shown in patients with interictal
hypoperfusion in surgically intractable epilepsy [203] and tu-
berous sclerosis [204]. PASL also compares favourably to PET
and electrical source imaging in identifying the epileptogenic
zone [205], indicating diagnostic value and potential utility in
guiding intracranial electrode placement. Recent work demon-
strated comparable measurements between PASL and DSC for
detecting seizure-associated perfusion asymmetries [206].
Ictal ASL measurements have only been reported in
case studies, as seizures must coincidentally occur during
scans. One patient’s complex partial seizure during PASL
acquisition showed ictal hyperperfusion in the typical sei-
zure focus, a finding that was not present interictally
[207]. This matches the underlying pathophysiological
mechanism of a seizure; excess activation requires in-
creased blood flow to deliver glucose and oxygen. Oishi
et al. [208] captured PASL images of a patient during and
after partial status epilepticus. The case study followed
the same trends, with marked hyperperfusion in the epi-
leptogenic zone during the seizures and hypoperfusion
compared to the non-affected hemisphere once the sei-
zures stopped. Finally, Kanzawa et al. report that the com-
bined use of ASL and DWI was useful in differentiating
non-convulsive partial status epilepticus from stroke when
ictal discharges were not captured with EEG, leading to
appropriate treatment and resolution of symptoms [209].
Ictal perfusion imaging provides better information
than interictal imaging alone [210]. Since ictal SPECT
only depends on injection time whereas ictal ASL re-
quires simultaneous scanning, which is not typically com-
patible with electroencephalography, regular utility of
ASL is currently limited to interictal foci lateralisation.
Perfusion quantification can also yield valuable insight
into seizure-causing lesions such as cortical dysplasia
[211]. Identification of such lesions is vital for pre-
surgical planning and operative outcome.
Fig. 14 Zoomed in sagittal views
of high-resolution T1-weighted
images without (a) and with (b)
CBF map overlay. Coloured ASL
voxels include grey matter, white
matter, and cerebrospinal fluid
simultaneously, illustrating the
partial volume effect. Partial
volume effects can be dealt with
by using a post-processing
technique called partial volume
correction [181]
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Psychiatric disease
The use of ASL in exploring the neurobiological and anatom-
ical correlates of clinical psychiatric conditions is steadily in-
creasing. It is thought that cerebral microvasculature abnor-
malities may play a role in some psychiatric illnesses, the
mechanisms of which are poorly understood [212], but chang-
es in regional CBF are generally attributed to changes in neu-
ronal activity and energy demand secondary to psychiatric
disease or its therapy.
Baseline differences in CBF between patients and healthy
controls have been identified in several ASL studies. Chronic
and treatment-resistant depression showed associated perfu-
sion abnormalities in the pathologically relevant subgenual
anterior cingulate cortex compared to healthy controls [213].
Adolescent depression appears to affect regional CBF mea-
surements in executive, affective, and motor networks [214].
Late-life depression has been associated with elevation of
white matter CBF [215]. Schizophrenia has been correlated
with hypoperfusion of the prefrontal cortex [216–218], in ad-
dition to complex patterns of altered perfusion in other brain
areas. Borderline personality disorder was associated with de-
creased CBF in the medial orbitofrontal cortex and increased
CBF in the lateral orbitofrontal cortex compared to healthy
controls [219].
ASL may also be used to assess treatments. Regional CBF
measurements have been shown to predict response of pa-
tients with depression [220] and schizophrenia [221] to repet-
itive transcranial magnetic stimulation, indicating potential for
individualised therapy. Studies isolating the effects of pharma-
ceuticals on brain perfusion in healthy subjects allow for
greater understanding of their application in psychiatric
conditions, where changes in regional perfusion can compli-
cate such assessment [222–224].
Territorial ASL
Territorial ASL refers to the ASL method that provides a per-
fusion measurement from a specific vascular territory
(Fig. 15). The original methods, based on PASL sequences,
allowed for a separation mostly of each of the two perfusion
territories from the internal carotid arteries (ICAs), and the
posterior territory, without distinction between ACA and
MCA territories or between left and right vertebral arteries
[225]. More recent methods, based on pCASL, allow for a
much finer assessment of the perfusion territories from smaller
arteries, with the caveat that separate measurements from the
ACA and MCA will require imaging of perfusion in tissues
distal to the circle of Willis and will therefore never be able to
produce whole brain perfusion maps [226]. For an extensive
review on all territorial ASL methods, the reader is directed to
Hartkamp et al. [227]. Territorial ASL has been used in many
studies of sub-acute stroke and has shown to provide addition-
al information on the underlying pathology of lateralised le-
sions. In particular, it has been shown that in about 10 % of
patients with a cortical lesion, assessment of the anatomical
location alone results in a misclassification of the perfusion
territory in which the infarct is located. The availability of a
vascular territorial perfusion map allows to correct this [82].
An additional potential application of territorial ASL is in the
context of steno-occlusive disease, when both information on
the affected vessel’s perfusion territory and an assessment of
cerebrovascular reserve capacity can be obtained.
Fig. 15 Positioning of the selective labeling planes for territorial ASL
based on an MR angiogram of the circle of Willis for the right internal
carotid artery (ICA, red box) and the basilar artery (blue box). The labeling
plane for the left ICA is not shown, as this vessel was occluded and no
signal was obtained. b Colour territorial perfusion maps showing the
distribution of brain tissue perfused by the intracranial arteries labeled
in (a). The anterior and middle cerebral artery territories in both
hemispheres are supplied by the right ICA in this patient with left ICA
occlusion (in red). The medial occipital and parietal lobes are supplied by
the basilar artery (in blue)
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Conclusion
ASL is now commercially available on MRI systems from all
major vendors and is increasingly making its way into clinical
practice. Its non-invasive and quantitative nature makes the
technique especially attractive for vulnerable patient popula-
tions, such as the elderly, children, oncological patients with
difficult venous access, and patients with renal insufficiency.
There is currently sufficient evidence to support its clinical
application in dementia, neuro-oncology and cerebrovascular
disease, with clear advantages in terms of improved and earlier
diagnosis. With the current tremendous research efforts in other
areas of neurological and psychiatric disease, it can be expected
that additional clinical indications will arise in the near future.
Acknowledgments This study is supported by the EU COST Action
BM1103 on ASL in Dementia.
Ethical standards and patient consent We declare that this manu-
script does not contain clinical studies or patient data.
Conflict of interest XG is the Director, Gold Standard Phantoms
Limited.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. WintermarkM, SesayM, Barbier E et al (2005) Comparative over-
view of brain perfusion imaging techniques. Stroke 36(9):e83–e99
2. Williams DS, Detre JA, Leigh JS, Koretsky AP (1992) Magnetic
resonance imaging of perfusion using spin inversion of arterial
water. Proc Natl Acad Sci U S A 89(1):212–216
3. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic
systemic fibrosis: risk factors and incidence estimation. Radiology
243(1):148–157
4. Wang J, Licht DJ, Jahng G-H et al (2003) Pediatric perfusion
imaging using pulsed arterial spin labeling. J Magn Reson
Imaging 18(4):404–413
5. Wolf RL, Detre JA (2007) Clinical neuroimaging using arterial
spin-labeled perfusion magnetic resonance imaging.
Neurotherapeutics 4(3):346–359
6. Gevers S,MajoieCBLM, van denTweelXWet al (2009)Acquisition
time and reproducibility of continuous arterial spin-labeling perfusion
imaging at 3T. AJNR Am J Neuroradiol 30(5):968–971
7. Jiang L, Kim M, Chodkowski B et al (2010) Reliability and re-
producibility of perfusion MRI in cognitively normal subjects.
Magn Reson Imaging 28(9):1283–1289
8. Wang Y, Saykin AJ, Pfeuffer J et al (2011) Regional reproducibil-
ity of pulsed arterial spin labeling perfusion imaging at 3T.
Neuroimage 54(2):1188–1195
9. Mutsaerts HJMM, Steketee RME, Heijtel DFR et al (2014) Inter-
vendor reproducibility of pseudo-continuous arterial spin labeling
at 3 tesla. PLoS One 9(8), e104108
10. Golay X, Hendrikse J, Lim TCC (2004) Perfusion imaging using
arterial spin labeling. Top Magn Reson Imaging 15(1):10–27
11. Petersen ET, Zimine I, Ho Y-CL, Golay X (2006) Non-invasive
measurement of perfusion: a critical review of arterial spin label-
ling techniques. Br J Radiol 79(944):688–701
12. Liu TT, Wong EC, Buxton RB (2009) Perfusion MRI. In: Squire
E-IR (ed) Encyclopedia of neuroscience. Academic Press, Oxford,
pp 543–549
13. Golay X, Guenther M (2012) Arterial spin labelling: final steps to
make it a clinical reality. MAGMA 25(2):79–82
14. Detre JA, Rao H, Wang DJJ et al (2012) Applications of arterial
spin labeled MRI in the brain. J Magn Reson Imaging 35(5):1026–
1037
15. Essig M, Shiroishi MS, Nguyen TB et al (2013) Perfusion MRI:
the five most frequently asked technical questions. AJR Am J
Roentgenol 200(1):24–34
16. Alsop DC, Detre JA, Golay X et al (2014) Recommended imple-
mentation of arterial spin-labeled perfusion MRI for clinical appli-
cations: a consensus of the ISMRM perfusion study group and the
European consortium for ASL in dementia. Magn Reson Med
73(1):102–116
17. Maccotta L, Detre JA, Alsop DC (1997) The efficiency of adia-
batic inversion for perfusion imaging by arterial spin labeling.
NMR Biomed 10(4–5):216–221
18. Utting JF, Thomas DL, Gadian DG, Ordidge RJ (2003) Velocity-
driven adiabatic fast passage for arterial spin labeling: results from
a computer model. Magn Reson Med 49(2):398–401
19. Gach HM, Dai W (2004) Simple model of double adiabatic inver-
sion (DAI) efficiency. Magn Reson Med 52(4):941–946
20. Trampel R, Jochimsen TH, Mildner T et al (2004) Efficiency of
flow-driven adiabatic spin inversion under realistic experimental
conditions: a computer simulation. Magn Reson Med 51(6):1187–
1193
21. Buxton RB, Frank LR, Wong EC et al (1998) A general kinetic
model for quantitative perfusion imaging with arterial spin label-
ing. Magn Reson Med 40(3):383–396
22. Wong EC (2014) An introduction to ASL labeling techniques. J
Magn Reson Imaging 40(1):1–10
23. Henkelman RM, Huang X, Xiang QS et al (1993) Quantitative
interpretation of magnetization transfer. Magn Reson Med 29(6):
759–766
24. Detre JA, Leigh JS, Williams DS, Koretsky AP (1992) Perfusion
imaging. Magn Reson Med 23(1):37–45
25. Pizzini F, Smits M, Wesolowski R et al (2015) Arterial spin label-
ing. In: Saremi F (ed) Advances in noninvasive perfusion imaging:
a multimodality diagnostic approach to tissue perfusion analysis.
Lippincott Williams & Williams, Philadelphia
26. Kim SG (1995) Quantification of relative cerebral blood flow
change by flow-sensitive alternating inversion recovery (FAIR)
technique: application to functional mapping. Magn Reson Med
34(3):293–301
27. Wong EC, Buxton RB, Frank LR (1997) Implementation of quan-
titative perfusion imaging techniques for functional brain mapping
using pulsed arterial spin labeling. NMR Biomed 10(4–5):237–
249
28. Edelman RR, Chen Q (1998) EPISTARMRI: multislice mapping
of cerebral blood flow. Magn Reson Med 40(6):800–805
29. Garcia DM, Duhamel G, Alsop DC (2005) Efficiency of inversion
pulses for background suppressed arterial spin labeling. Magn
Reson Med 54(2):366–372
30. Oshio K, Feinberg DA (1991) GRASE (gradient- and spin-echo)
imaging: a novel fast MRI technique. Magn Reson Med 20(2):
344–349
31. Mulkern RV, Wong ST, Winalski C, Jolesz FA (1990) Contrast
manipulation and artifact assessment of 2D and 3D RARE se-
quences. Magn Reson Imaging 8(5):557–566
Neuroradiology (2015) 57:1181–1202 1197
32. Vidorreta M,Wang Z, Rodríguez I et al (2013) Comparison of 2D
and 3D single-shot ASL perfusion fMRI sequences. Neuroimage
66:662–671
33. Pruessmann KP, Weiger M, Scheidegger MB, Boesiger P (1999)
SENSE: sensitivity encoding for fast MRI. Magn Reson Med
42(5):952–962
34. Lu H, Nagae-Poetscher LM, Golay X et al (2005) Routine clinical
brain MRI sequences for use at 3.0 tesla. J Magn Reson Imaging
22(1):13–22
35. Wang J, Alsop DC, Li L et al (2002) Comparison of quantitative
perfusion imaging using arterial spin labeling at 1.5 and 4.0 tesla.
Magn Reson Med 48(2):242–254
36. Franke C, van Dorsten FA, Olah L et al (2000) Arterial spin tag-
ging perfusion imaging of rat brain: dependency on magnetic field
strength. Magn Reson Imaging 18(9):1109–1113
37. St Lawrence KS, Wang J (2005) Effects of the apparent transverse
relaxation time on cerebral blood flow measurements obtained by
arterial spin labeling. Magn Reson Med 53(2):425–433
38. Biagi L, Abbruzzese A, Bianchi MC et al (2007) Age dependence
of cerebral perfusion assessed by magnetic resonance continuous
arterial spin labeling. J Magn Reson Imaging 25(4):696–702
39. Deibler AR, Pollock JM, Kraft RA et al (2008) Arterial spin-
labeling in routine clinical practice, part 2: hypoperfusion patterns.
AJNR Am J Neuroradiol 29(7):1235–1241
40. Deibler AR, Pollock JM, Kraft RA et al (2008) Arterial spin-
labeling in routine clinical practice, part 3: hyperperfusion pat-
terns. AJNR Am J Neuroradiol 29(8):1428–1435
41. Detre JA, Alsop DC, Vives LR et al (1998) Noninvasive MRI
evaluation of cerebral blood flow in cerebrovascular disease.
Neurology 50(3):633–641
42. Detre JA, Samuels OB, Alsop DC et al (1999) Noninvasive mag-
netic resonance imaging evaluation of cerebral blood flow with
acetazolamide challenge in patients with cerebrovascular stenosis.
J Magn Reson Imaging 10(5):870–875
43. Kamano H, Yoshiura T, Hiwatashi A et al (2013) Arterial spin
labeling in patients with chronic cerebral artery steno-occlusive
disease: correlation with 15O-PET. Acta Radiol 54(1):99–106
44. Gevers S, Bokkers RP, Hendrikse J et al (2012) Robustness and
reproducibility of flow territories defined by planning-free vessel-
encoded pseudocontinuous arterial spin-labeling. AJNR Am J
Neuroradiol 33(2):E21–E25
45. MacIntosh BJ, Lindsay AC, Kylintireas I et al (2010) Multiple
inflow pulsed arterial spin-labeling reveals delays in the arterial
arrival time in minor stroke and transient ischemic attack. AJNR
Am J Neuroradiol 31(10):1892–1894
46. Parkes LM, Rashid W, Chard DT, Tofts PS (2004) Normal cerebral
perfusion measurements using arterial spin labeling: reproducibility,
stability, and age and gender effects. Magn Reson Med 51(4):736–
743
47. Brumm KP, Perthen JE, Liu TTet al (2010) An arterial spin label-
ing investigation of cerebral blood flow deficits in chronic stroke
survivors. Neuroimage 51(3):995–1005
48. Bokkers RPH, Bremmer JP, van Berckel BNM et al (2010)
Arterial spin labeling perfusion MRI at multiple delay times: a
correlative study with H(2)(15)O positron emission tomography
in patients with symptomatic carotid artery occlusion. J Cereb
Blood Flow Metab 30(1):222–229
49. Macintosh BJ, Marquardt L, Schulz UG et al (2012) Hemodynamic
alterations in vertebrobasilar large artery disease assessed by arterial
spin-labeling MR imaging. AJNR Am J Neuroradiol 33(10):1939–
1944
50. Martin SZ,Madai VI, von Samson-Himmelstjerna FC et al (2015)
3D GRASE pulsed arterial spin labeling at multiple inflow times
in patients with long arterial transit times: comparison with dy-
namic susceptibility-weighted contrast-enhanced MRI at 3 tesla. J
Cereb Blood Flow Metab 35(3):392–401
51. Hendrikse J, vanOschMJP, Rutgers DR et al (2004) Internal carotid
artery occlusion assessed at pulsed arterial spin-labeling perfusion
MR imaging at multiple delay times. Radiology 233(3):899–904
52. Kimura H, Kado H, Koshimoto Y et al (2005) Multislice contin-
uous arterial spin-labeled perfusion MRI in patients with chronic
occlusive cerebrovascular disease: a correlative study with CO2
PET validation. J Magn Reson Imaging 22(2):189–198
53. Bokkers RPH, van der Worp HB, Mali WPTM, Hendrikse J
(2009) Noninvasive MR imaging of cerebral perfusion in patients
with a carotid artery stenosis. Neurology 73(11):869–875
54. Uchihashi Y, Hosoda K, Zimine I et al (2011) Clinical application
of arterial spin-labeling MR imaging in patients with carotid ste-
nosis: quantitative comparative study with single-photon emission
CT. AJNR Am J Neuroradiol 32(8):1545–1551
55. Yun TJ, Sohn C-H, Han MH et al (2013) Effect of carotid artery
stenting on cerebral blood flow: evaluation of hemodynamic chang-
es using arterial spin labeling. Neuroradiology 55(3):271–281
56. Zaharchuk G, Do HM,MarksMP et al (2011) Arterial spin-labeling
MRI can identify the presence and intensity of collateral perfusion in
patients with moyamoya disease. Stroke 42(9):2485–2491
57. Donahue MJ, Ayad M, Moore R et al (2013) Relationships be-
tween hypercarbic reactivity, cerebral blood flow, and arterial cir-
culation times in patients with moyamoya disease. J Magn Reson
Imaging 38(5):1129–1139
58. Noguchi T, Kawashima M, Irie H et al (2011) Arterial spin-
labeling MR imaging in moyamoya disease compared with
SPECT imaging. Eur J Radiol 80(3):e557–e562
59. Goetti R, Warnock G, Kuhn FP et al (2014) Quantitative cerebral
perfusion imaging in children and young adults with moyamoya
disease: comparison of arterial spin-labeling-MRI and H2[15O]-
PET. AJNR Am J Neuroradiol 35(5):1022–1028
60. Margariti P, Sanchez-Montanez A, Delgado I et al (2013) At-risk
brain tissue identified with arterial spin labeling in
neurotuberculosis. Pediatr Radiol 43(8):1049–1052
61. Ishitobi M, YonedaM, IkawaM et al (2013) Hashimoto’s enceph-
alopathy with hippocampus involvement detected on continuous
arterial spin labeling. Psychiatry Clin Neurosci 67(2):128–129
62. Fiehler J, Illies T, Piening M et al (2009) Territorial and microvas-
cular perfusion impairment in brain arteriovenous malformations.
AJNR Am J Neuroradiol 30(2):356–361
63. Suazo L, Foerster B, Fermin R et al (2012) Measurement of blood
flow in arteriovenousmalformations before and after embolization
using arterial spin labeling. Interv Neuroradiol 18(1):42–48
64. Amponsah K, Ellis TL, Chan MD et al (2012) Retrospective anal-
ysis of imaging techniques for treatment planning and monitoring
of obliteration for gamma knife treatment of cerebral arteriove-
nous malformation. Neurosurgery 71(4):893–899
65. Shimizu K, Kosaka N, Yamamoto T, et al. (2014) Arterial spin
labeling perfusion-weighted MRI for long-term follow-up of a
cerebral arteriovenous malformation after stereotactic radiosur-
gery. Acta Radiol Short Rep 3(1)
66. Yu SL, Wang R, Wang S et al (2014) Accuracy of vessel-encoded
pseudocontinuous arterial spin-labeling in identification of feeding
arteries in patients with intracranial arteriovenous malformations.
AJNR Am J Neuroradiol 35(1):65–71
67. Aoyama K, Fushimi Y, Okada T et al (2012) Detection of symp-
tomatic vasospasm after subarachnoid haemorrhage: initial find-
ings from single time-point and serial measurements with arterial
spin labelling. Eur Radiol 22(11):2382–2391
68. Saida T, Masumoto T, Nakai Y et al (2012) Moyamoya disease:
evaluation of postoperative revascularization using multiphase se-
lective arterial spin labeling MRI. J Comput Assist Tomogr 36(1):
143–149
69. Zhao WG, Luo Q, Jia JB, Yu JL (2013) Cerebral hyperperfusion
syndrome after revascularization surgery in patients with
moyamoya disease. Br J Neurosurg 27(3):321–325
1198 Neuroradiology (2015) 57:1181–1202
70. Zheng G, Zhang LJ, Wang Z et al (2012) Changes in cerebral
blood flow after transjugular intrahepatic portosystemic shunt
can help predict the development of hepatic encephalopathy: an
arterial spin labeling MR study. Eur J Radiol 81(12):3851–3856
71. Liu AA, Voss HU, Dyke JP et al (2011) Arterial spin labeling and
altered cerebral blood flow patterns in the minimally conscious
state. Neurology 77(16):1518–1523
72. Pollock JM, Whitlow CT, Deibler AR et al (2008) Anoxic injury-
associated cerebral hyperperfusion identified with arterial spin-
labeled MR imaging. AJNR Am J Neuroradiol 29(7):1302–1307
73. Wang Z, Xiao J, Xie S et al (2012) MR evaluation of cerebral
oxygen metabolism and blood flow in stroke-like episodes of
MELAS. J Neurol Sci 323(1–2):173–177
74. Rothwell PM, Giles MF, Chandratheva A et al (2007) Effect of
urgent treatment of transient ischaemic attack and minor stroke on
early recurrent stroke (EXPRESS study): a prospective population-
based sequential comparison. Lancet 370(9596):1432–1442
75. Kleinman JT, Zaharchuk G, Mlynash M et al (2012) Automated
perfusion imaging for the evaluation of transient ischemic attack.
Stroke 43(6):1556–1560
76. Zaharchuk G, Olivot J-M, Fischbein NJ et al (2012) Arterial spin
labeling imaging findings in transient ischemic attack patients:
comparison with diffusion- and bolus perfusion-weighted imag-
ing. Cerebrovasc Dis 34(3):221–228
77. Qiao XJ, Salamon N, Wang DJJ et al (2013) Perfusion deficits
detected by arterial spin-labeling in patients with TIA with nega-
tive diffusion and vascular imaging. AJNR Am J Neuroradiol
34(11):2125–2130
78. Wang DJJ, Alger JR, Qiao JX et al (2012) The value of arterial
spin-labeled perfusion imaging in acute ischemic stroke: compar-
ison with dynamic susceptibility contrast-enhanced MRI. Stroke
43(4):1018–1024
79. Nael K, Meshksar A, Liebeskind DS et al (2013) Periprocedural
arterial spin labeling and dynamic susceptibility contrast perfusion
in detection of cerebral blood flow in patients with acute ischemic
syndrome. Stroke 44(3):664–670
80. Bokkers RPH, Hernandez DA, Merino JG et al (2012) Whole-
brain arterial spin labeling perfusion MRI in patients with acute
stroke. Stroke 43(5):1290–1294
81. Zaharchuk G, El Mogy IS, Fischbein NJ, Albers GW (2012)
Comparison of arterial spin labeling and bolus perfusion-
weighted imaging for detecting mismatch in acute stroke. Stroke
43(7):1843–1848
82. Hendrikse J, Petersen ET, Chèze A et al (2009) Relation between
cerebral perfusion territories and location of cerebral infarcts.
Stroke 40(5):1617–1622
83. Chalela JA, Alsop DC, Gonzalez-Atavales JB et al (2000)
Magnetic resonance perfusion imaging in acute ischemic stroke
using continuous arterial spin labeling. Stroke 31(3):680–687
84. Fernández-Seara MA, Edlow BL, Hoang A et al (2008)
Minimizing acquisition time of arterial spin labeling at 3T.
Magn Reson Med 59(6):1467–1471
85. Chen T-Y, Chiu L, Wu T-C et al (2012) Arterial spin-labeling in
routine clinical practice: a preliminary experience of 200 cases and
correlation with MRI and clinical findings. Clin Imaging 36(4):
345–352
86. Chen J, Licht DJ, Smith SE et al (2009) Arterial spin labeling
perfusion MRI in pediatric arterial ischemic stroke: initial experi-
ences. J Magn Reson Imaging 29(2):282–290
87. Wintermark P, Warfield SK (2012) New insights in perinatal arte-
rial ischemic stroke by assessing brain perfusion. Trans Stroke Res
3(2):255–262
88. Pienaar R, Paldino MJ, Madan N et al (2012) A quantitative method
for correlating observations of decreased apparent diffusion coeffi-
cient with elevated cerebral blood perfusion in newborns presenting
cerebral ischemic insults. Neuroimage 63(3):1510–1518
89. Njemanze PC, Beck OJ, Gomez CR et al (1991) North american
symptomatic carotid endarterectomy trial. Methods, patient char-
acteristics, and progress. Stroke 22(6):711–720
90. European Carotid Surgery Trialists’ Collaborative Group (1998)
Randomised trial of endarterectomy for recently symptomatic ca-
rotid stenosis: final results of the MRC European Carotid Surgery
Trial (ECST). Lancet 351(9113):1379–1387
91. Stoll M, Hamann GF (2002) Cerebrovascular reserve capacity.
Nervenarzt 73(8):711–718
92. Bokkers RPH, Osch MJPV, Klijn CJM et al (2011)
Cerebrovascular reactivity within perfusion territories in patients
with an internal carotid artery occlusion. J Neurol, Neurosurg
Psychiatry 82(9):1011–1016
93. Siero JCW, Hartkamp NS, Donahue MJ et al (2015) Neuronal
activation induced BOLD and CBF responses upon acetazolamide
administration in patients with steno-occlusive artery disease.
Neuroimage 105:276–285
94. Van Laar PJ, Hendrikse J, Mali WPTM et al (2007) Altered flow
territories after carotid stenting and carotid endarterectomy. J Vasc
Surg 45(6):1155–1161
95. Hesselink JR (2006) Differential diagnostic approach to MR im-
aging of white matter diseases. Top Magn Reson Imaging 17(4):
243–263
96. Zhang Q, Stafford RB, Wang Z et al (2012) Microvascular perfu-
sion based on arterial spin labeled perfusion MRI as a measure of
vascular risk in Alzheimer’s disease. J Alzheimers Dis 32(3):677–
687
97. Bastos-Leite AJ, Kuijer JPA, Rombouts SARB et al (2008)
Cerebral blood flow by using pulsed arterial spin-labeling in el-
derly subjects with white matter hyperintensities. AJNR Am J
Neuroradiol 29(7):1296–1301
98. van Osch MJP, Teeuwisse WM, van Walderveen MAA et al
(2009) Can arterial spin labeling detect white matter perfusion
signal? Magn Reson Med 62(1):165–173
99. Mutsaerts HJMM, Richard E, Heijtel DFR et al (2013) Gray mat-
ter contamination in arterial spin labeling white matter perfusion
measurements in patients with dementia. Neuroimage Clin 4:139–
144
100. Wang DJJ, Alger JR, Qiao JX et al (2013) Multi-delay multi-
parametric arterial spin-labeled perfusion MRI in acute ischemic
stroke—comparison with dynamic susceptibility contrast en-
hanced perfusion imaging. Neuroimage Clin 3:1–7
101. Alsop DC, Detre JA (1996) Reduced transit-time sensitivity in
noninvasivemagnetic resonance imaging of human cerebral blood
flow. J Cereb Blood Flow Metab 16(6):1236–1249
102. Yoo R-E, Yun TJ, Rhim JH et al (2015) Bright vessel appearance
on arterial spin labeling MRI for localizing arterial occlusion in
acute ischemic stroke. Stroke 46(2):564–567
103. Wang J, Alsop DC, Song HK et al (2003) Arterial transit time
imaging with flow encoding arterial spin tagging (FEAST).
Magn Reson Med 50(3):599–607
104. ZaharchukG, Bammer R, StrakaM et al (2009) Arterial spin-label
imaging in patients with normal bolus perfusion-weighted MR
imaging findings: pilot identification of the borderzone sign.
Radiology 252(3):797–807
105. Chng SM, Petersen ET, Zimine I et al (2008) Territorial arterial spin
labeling in the assessment of collateral circulation: comparison with
digital subtraction angiography. Stroke 39(12):3248–3254
106. Huang Y-C, Liu H-L, Lee J-D et al (2013) Comparison of arterial
spin labeling and dynamic susceptibility contrast perfusionMRI in
patients with acute stroke. PLoS One 8(7), e69085
107. Wolf RL, Wang J, Detre JA et al (2008) Arteriovenous shunt
visualization in arteriovenous malformations with arterial spin-
labeling MR imaging. AJNR Am J Neuroradiol 29(4):681–687
108. Brayne C, Davis D (2012) Making Alzheimer’s and dementia
research fit for populations. Lancet 380(9851):1441–1443
Neuroradiology (2015) 57:1181–1202 1199
109. McMahon PM, Araki SS, Sandberg EA et al (2003) Cost-
effectiveness of PET in the diagnosis of Alzheimer disease.
Radiology 228(2):515–522
110. Donahue MJ, Lu H, Jones CK et al (2006) An account of the
discrepancy betweenMRI and PETcerebral blood flowmeasures.
A high-field MRI investigation. NMR Biomed 19(8):1043–1054
111. Xu G, Rowley HA, Wu G et al (2010) Reliability and precision of
pseudo-continuous arterial spin labeling perfusion MRI on 3.0 T
and comparison with 15o-water PET in elderly subjects at risk for
Alzheimer’s disease. NMR Biomed 23(3):286–293
112. Wolk DA, Detre JA (2012) Arterial spin labeling MRI: an emerg-
ing biomarker for Alzheimer’s disease and other neurodegenera-
tive conditions. Curr Opin Neurol 25(4):421–428
113. Chen Y, Wolk DA, Reddin JS et al (2011) Voxel-level comparison
of arterial spin-labeled perfusionMRI and FDG-PET in Alzheimer
disease. Neurology 77(22):1977–1985
114. Musiek ES, Chen Y, Korczykowski M et al (2012) Direct compar-
ison of fluorodeoxyglucose positron emission tomography and
arterial spin labeling magnetic resonance imaging in Alzheimer’s
disease. Alzheimers Dement 8(1):51–59
115. Austin BP, Nair VA, Meier TB et al (2011) Effects of hypoperfu-
sion in Alzheimer’s disease. J Alzheimers Dis 26(Suppl 3):123–
133
116. Alexopoulos P, Sorg C, Förschler A et al (2012) Perfusion abnor-
malities in mild cognitive impairment and mild dementia in
Alzheimer’s disease measured by pulsed arterial spin labeling
MRI. Eur Arch Psychiatry Clin Neurosci 262(1):69–77
117. Yoshiura T, Hiwatashi A, Noguchi T et al (2009) Arterial spin
labelling at 3-T MR imaging for detection of individuals with
Alzheimer’s disease. Eur Radiol 19(12):2819–2825
118. Mak HKF, Chan Q, Zhang Z et al (2012) Quantitative assessment
of cerebral hemodynamic parameters by QUASAR arterial spin
labeling in Alzheimer’s disease and cognitively normal elderly
adults at 3-tesla. J Alzheimers Dis 31(1):33–44
119. Hu WT, Wang Z, Lee VM-Y et al (2010) Distinct cerebral perfu-
sion patterns in FTLD and AD. Neurology 75(10):881–888
120. Du AT, Jahng GH, Hayasaka S et al (2006) Hypoperfusion in
frontotemporal dementia and Alzheimer disease by arterial spin
labeling MRI. Neurology 67(7):1215–1220
121. Steketee RME, Bron EE, Meijboom R, et al. (2015) Early-stage
differentiation between presenile Alzheimer’s disease and
frontotemporal dementia using arterial spin labeling MRI. Eur
Radiol
122. Chao LL, Buckley ST, Kornak J et al (2010) ASL perfusion MRI
predicts cognitive decline and conversion from MCI to dementia.
Alzheimer Dis Assoc Disord 24(1):19–27
123. Kim SM, KimMJ, Rhee HYet al (2013) Regional cerebral perfu-
sion in patients with Alzheimer’s disease and mild cognitive im-
pairment: effect of APOE epsilon4 allele. Neuroradiology 55(1):
25–34
124. Dashjamts T, Yoshiura T, Hiwatashi A et al (2011) Simultaneous
arterial spin labeling cerebral blood flow and morphological as-
sessments for detection of Alzheimer’s disease. Acad Radiol
18(12):1492–1499
125. Bron EE, Steketee RME, Houston GC et al (2014) Diagnostic
classification of arterial spin labeling and structural MRI in
presenile early stage dementia. Hum Brain Mapp 35(9):4916–
4931
126. Zou J-X, Wang M-J, Lei X-J, Chen X-G (2014) 3.0T MRI arterial
spin labeling and magnetic resonance spectroscopy technology in
the application of Alzheimer’s disease. Exp Gerontol 60:31–36
127. Wang Z (2014) Characterizing early Alzheimer’s disease and dis-
ease progression using hippocampal volume and arterial spin la-
beling perfusion MRI. J Alzheimers Dis 42(Suppl 4):S495–S502
128. Schuff N, Matsumoto S, Kmiecik J et al (2009) Cerebral blood
flow in ischemic vascular dementia and Alzheimer’s disease,
measured by arterial spin-labeling magnetic resonance imaging.
Alzheimers Dement 5(6):454–462
129. Yoshiura T, Hiwatashi A, Yamashita K et al (2009) Simultaneous
measurement of arterial transit time, arterial blood volume, and
cerebral blood flow using arterial spin-labeling in patients with
Alzheimer disease. AJNR Am J Neuroradiol 30(7):1388–1393
130. Mazza M, Marano G, Traversi G et al (2011) Primary cerebral
blood flow deficiency and Alzheimer’s disease: shadows and
lights. J Alzheimers Dis 23(3):375–389
131. Raji CA, Lee C, Lopez OL et al (2010) Initial experience in using
continuous arterial spin-labeled MR imaging for early detection of
Alzheimer disease. AJNR Am J Neuroradiol 31(5):847–855
132. Wierenga CE, Hays CC, Zlatar ZZ (2014) Cerebral blood flow
measured by arterial spin labeling MRI as a preclinical marker of
Alzheimer’s disease. J Alzheimers Dis 42(Suppl 4):S411–S419
133. Wang Z, Das SR, Xie SX et al (2013) Arterial spin labeledMRI in
prodromal Alzheimer’s disease: a multi-site study. NeuroImage:
Clin 2:630–636
134. Alsop DC, Detre JA, Grossman M (2000) Assessment of cerebral
blood flow in Alzheimer’s disease by spin-labeled magnetic reso-
nance imaging. Ann Neurol 47(1):93–100
135. Johnson NA, Jahng G-H, Weiner MW et al (2005) Pattern of
cerebral hypoperfusion in Alzheimer disease and mild cognitive
impairment measured with arterial spin-labeling MR imaging: ini-
tial experience. Radiology 234(3):851–859
136. Alsop DC, Casement M, de Bazelaire C et al (2008) Hippocampal
hyperperfusion in Alzheimer’s disease. Neuroimage 42(4):1267–
1274
137. Asllani I, Habeck C, Scarmeas N et al (2008) Multivariate and
univariate analysis of continuous arterial spin labeling perfusion
MRI in Alzheimer’s disease. J Cereb Blood Flow Metab 28(4):
725–736
138. Ances BM, Liang CL, Leontiev O et al (2009) Effects of aging on
cerebral blood flow, oxygen metabolism, and blood oxygenation
level dependent responses to visual stimulation. Hum Brain Mapp
30(4):1120–1132
139. Dai W, Lopez OL, Carmichael OT et al (2009) Mild cognitive
impairment and Alzheimer disease: patterns of altered cerebral
blood flow at MR imaging. Radiology 250(3):856–866
140. Binnewijzend MAA, Kuijer JPA, Benedictus MR et al (2013)
Cerebral blood flow measured with 3D pseudocontinuous arterial
spin-labeling MR imaging in Alzheimer disease and mild cogni-
tive impairment: a marker for disease severity. Radiology 267(1):
221–230
141. Pfefferbaum A, Chanraud S, Pitel A-L et al (2010) Volumetric
cerebral perfusion imaging in healthy adults: regional distribution,
laterality, and repeatability of pulsed continuous arterial spin la-
beling (PCASL). Psychiatry Res 182(3):266–273
142. Lüdemann L, Warmuth C, Plotkin M et al (2009) Brain tumor
perfusion: comparison of dynamic contrast enhanced magnetic
resonance imaging using T1, T2, and T2* contrast, pulsed arterial
spin labeling, and H2(15)O positron emission tomography. Eur J
Radiol 70(3):465–474
143. Lehmann P, Monet P, de Marco G et al (2010) A comparative
study of perfusion measurement in brain tumours at 3 tesla MR:
arterial spin labeling versus dynamic susceptibility contrast-
enhanced MRI. Eur Neurol 64(1):21–26
144. Järnum H, Steffensen EG, Knutsson L et al (2010) Perfusion MRI
of brain tumours: a comparative study of pseudo-continuous arte-
rial spin labelling and dynamic susceptibility contrast imaging.
Neuroradiology 52(4):307–317
145. Hirai T, Kitajima M, Nakamura H et al (2011) Quantitative blood
flow measurements in gliomas using arterial spin-labeling at 3T:
intermodality agreement and inter- and intraobserver reproducibil-
ity study. AJNR Am J Neuroradiol 32(11):2073–2079
1200 Neuroradiology (2015) 57:1181–1202
146. van Westen D, Petersen ET, Wirestam R et al (2011) Correlation
between arterial blood volume obtained by arterial spin labelling
and cerebral blood volume in intracranial tumours. MAGMA
24(4):211–223
147. Yamashita K, Yoshiura T, Hiwatashi A et al (2013) Differentiating
primary CNS lymphoma from glioblastoma multiforme: assess-
ment using arterial spin labeling, diffusion-weighted imaging, and
(18)f-fluorodeoxyglucose positron emission tomography.
Neuroradiology 55(2):135–143
148. Noguchi T, Yoshiura T, Hiwatashi A et al (2008) Perfusion imag-
ing of brain tumors using arterial spin-labeling: correlation with
histopathologic vascular density. AJNR Am J Neuroradiol 29(4):
688–693
149. Yamashita K, Yoshiura T, Hiwatashi A et al (2012) Arterial spin
labeling of hemangioblastoma: differentiation from metastatic
brain tumors based on quantitative blood flow measurement.
Neuroradiology 54(8):809–813
150. Nabavizadeh SA, Assadsangabi R, Hajmomenian M et al (2015)
High accuracy of arterial spin labeling perfusion imaging in dif-
ferentiation of pilomyxoid from pilocytic astrocytoma.
Neuroradiology 57(5):527–533
151. Wolf RL,Wang J,Wang S et al (2005) Grading of CNS neoplasms
using continuous arterial spin labeled perfusion MR imaging at 3
tesla. J Magn Reson Imaging 22(4):475–482
152. Chawla S,Wang S,Wolf RL et al (2007) Arterial spin-labeling and
MR spectroscopy in the differentiation of gliomas. AJNR Am J
Neuroradiol 28(9):1683–1689
153. Warmuth C, GuntherM, Zimmer C (2003)Quantification of blood
flow in brain tumors: comparison of arterial spin labeling and
dynamic susceptibility-weighted contrast-enhanced MR imaging.
Radiology 228(2):523–532
154. Weber MA, Zoubaa S, Schlieter M et al (2006) Diagnostic perfor-
mance of spectroscopic and perfusion MRI for distinction of brain
tumors. Neurology 66(12):1899–1906
155. Kim HS, Kim SY (2007) A prospective study on the added value
of pulsed arterial spin-labeling and apparent diffusion coefficients
in the grading of gliomas. AJNR Am J Neuroradiol 28(9):1693–
1699
156. Furtner J, Schöpf V, Schewzow K, et al. (2013) Arterial spin-
labeling assessment of normalized vascular intratumoral signal
intensity as a predictor of histologic grade of astrocytic neoplasms.
AJNR Am J Neuroradiol
157. Cebeci H, Aydin O, Ozturk-Isik E et al (2014) Assessment of
perfusion in glial tumors with arterial spin labeling; comparison
with dynamic susceptibility contrast method. Eur J Radiol 83(10):
1914–1919
158. Fellah S, Girard N, Chinot O et al (2011) Early evaluation of
tumoral response to antiangiogenic therapy by arterial spin label-
ing perfusion magnetic resonance imaging and susceptibility
weighted imaging in a patient with recurrent glioblastoma receiv-
ing bevacizumab. J Clin Oncol 29(11):e308–e311
159. Ozsunar Y, Mullins ME, Kwong K et al (2010) Glioma recurrence
versus radiation necrosis? A pilot comparison of arterial spin-la-
beled, dynamic susceptibility contrast enhanced MRI, and FDG-
PET imaging. Acad Radiol 17(3):282–290
160. Deibler AR, Pollock JM, Kraft RA et al (2008) Arterial spin-
labeling in routine clinical practice, part 1: technique and artifacts.
AJNR Am J Neuroradiol 29(7):1228–1234
161. Clement P, Mutsaerts H-J, Ghariq E et al (2014) Review of con-
founding effects on perfusionmeasurements. Front HumNeurosci 8
162. Takeuchi H, Taki Y, HashizumeH et al (2011) Cerebral blood flow
during rest associates with general intelligence and creativity.
PLoS One 6(9), e25532
163. O’Gorman RL, Kumari V, Williams SCR et al (2006) Personality
factors correlate with regional cerebral perfusion. Neuroimage
31(2):489–495
164. Ainslie PN, Cotter JD, George KP et al (2008) Elevation in cere-
bral blood flow velocity with aerobic fitness throughout healthy
human ageing. J Physiol 586(16):4005–4010
165. Chen JJ, Rosas HD, Salat DH (2011) Age-associated reductions in
cerebral blood flow are independent from regional atrophy.
Neuroimage 55(2):468–478
166. Paradiso S, Robinson RG, Boles Ponto LL et al (2003) Regional
cerebral blood flow changes during visually induced subjective
sadness in healthy elderly persons. J Neuropsychiatry Clin
Neurosci 15(1):35–44
167. Mardimae A, Balaban DY, Machina MA et al (2012) The interac-
tion of carbon dioxide and hypoxia in the control of cerebral blood
flow. Pflugers Arch 464(4):345–351
168. Page KA, Chan O, Arora J et al (2013) Effects of fructose vs
glucose on regional cerebral blood flow in brain regions involved
with appetite and reward pathways. JAMA 309(1):63–70
169. Wang J, Rao H, Wetmore GS et al (2005) Perfusion functional
MRI reveals cerebral blood flow pattern under psychological
stress. Proc Natl Acad Sci U S A 102(49):17804–17809
170. Addicott MA, Yang LL, Peiffer AM et al (2009) The effect of
daily caffeine use on cerebral blood flow: how much caffeine
can we tolerate? Hum Brain Mapp 30(10):3102–3114
171. Domino EF, Ni L, Xu Yet al (2004) Regional cerebral blood flow
and plasma nicotine after smoking tobacco cigarettes. Prog
Neuropsychopharmacol Biol Psychiatry 28(2):319–327
172. Jain V, Duda J, Avants B et al (2012) Longitudinal reproducibility
and accuracy of pseudo-continuous arterial spin-labeled perfusion
MR imaging in typically developing children. Radiology 263(2):
527–536
173. Goff DA, Buckley EM, Durduran T et al (2010) Noninvasive
cerebral perfusion imaging in high-risk neonates. Semin
Perinatol 34(1):46–56
174. Gevers S, Nederveen AJ, Fijnvandraat K et al (2012) Arterial spin
labeling measurement of cerebral perfusion in children with sickle
cell disease. J Magn Reson Imaging 35(4):779–787
175. Dahmoush HM, Vossough A, Roberts TPL (2012) Pediatric high-
field magnetic resonance imaging. Neuroimaging Clin N Am
22(2):297–313, xi
176. Herscovitch P, RaichleME (1985)What is the correct value for the
brain–blood partition coefficient for water? J Cereb Blood Flow
Metab 5(1):65–69
177. Lu H, Clingman C, Golay X, van Zijl PCM (2004) Determining
the longitudinal relaxation time (T1) of blood at 3.0 tesla. Magn
Reson Med 52(3):679–682
178. Lu H, Golay X, Pekar JJ, Van Zijl PCM (2003) Functional mag-
netic resonance imaging based on changes in vascular space oc-
cupancy. Magn Reson Med 50(2):263–274
179. Dai W, Garcia D, de Bazelaire C, Alsop DC (2008) Continuous
flow-driven inversion for arterial spin labeling using pulsed radio
frequency and gradient fields. MagnResonMed 60(6):1488–1497
180. Wong EC, Buxton RB, Frank LR (1998) A theoretical and exper-
imental comparison of continuous and pulsed arterial spin labeling
techniques for quantitative perfusion imaging. Magn Reson Med
40(3):348–355
181. Asllani I, Borogovac A, Brown TR (2008) Regression algorithm
correcting for partial volume effects in arterial spin labeling MRI.
Magn Reson Med 60(6):1362–1371
182. Melzer TR, Watts R, MacAskill MR et al (2011) Arterial spin
labelling reveals an abnormal cerebral perfusion pattern in
Parkinson’s disease. Brain 134(Pt 3):845–855
183. Fernández-Seara MA, Mengual E, Vidorreta M et al (2012)
Cortical hypoperfusion in Parkinson’s disease assessed using ar-
terial spin labeled perfusion MRI. Neuroimage 59(3):2743–2750
184. Wolf RC, Grön G, Sambataro F et al (2011) Magnetic resonance
perfusion imaging of resting-state cerebral blood flow in preclinical
Huntington’s disease. J Cereb Blood FlowMetab 31(9):1908–1918
Neuroradiology (2015) 57:1181–1202 1201
185. Chen JJ, Salat DH, Rosas HD (2012) Complex relationships be-
tween cerebral blood flow and brain atrophy in early Huntington’s
disease. Neuroimage 59(2):1043–1051
186. Ota M, Sato N, Nakata Y et al (2013) Abnormalities of cerebral
blood flow in multiple sclerosis: a pseudocontinuous arterial spin
labeling MRI study. Magn Reson Imaging 31(6):990–995
187. Paling D, Thade Petersen E, Tozer DJ et al (2014) Cerebral arterial
bolus arrival time is prolonged in multiple sclerosis and associated
with disability. J Cereb Blood Flow Metab 34(1):34–42
188. Marshall O, Lu H, Brisset J-C et al (2014) Impaired cerebrovas-
cular reactivity in multiple sclerosis. JAMA Neurol 71(10):1275–
1281
189. Golay X, Petersen ET (2006) Arterial spin labeling: benefits and
pitfalls of high magnetic field. Neuroimaging Clin N Am 16(2):
259–268, x
190. van Gelderen P, de Zwart JA, Duyn JH (2008) Pittfalls of MRI
measurement of white matter perfusion based on arterial spin la-
beling. Magn Reson Med 59(4):788–795
191. Zuo Z, Wang R, Zhuo Yet al (2013) Turbo-FLASH based arterial
spin labeled perfusion MRI at 7 T. PLoS One 8(6), e66612
192. Petersen ET, Lim T, Golay X (2006) Model-free arterial spin la-
beling quantification approach for perfusion MRI. Magn Reson
Med 55(2):219–232
193. Qiu D, Straka M, Zun Z et al (2012) CBF measurements using
multidelay pseudocontinuous and velocity-selective arterial spin
labeling in patients with long arterial transit delays: comparison
with xenon CT CBF. J Magn Reson Imaging 36(1):110–119
194. Duncan JS (2010) Imaging in the surgical treatment of epilepsy.
Nat Rev Neurol 6(10):537–550
195. Holmes GL (2002) Seizure-induced neuronal injury: animal data.
Neurology 59(9 Suppl 5):S3–S6
196. Duncan JS (2002) Seizure-induced neuronal injury: human data.
Neurology 59(9 Suppl 5):S15–S20
197. Choi J, Koh S (2008) Role of brain inflammation in
epileptogenesis. Yonsei Med J 49(1):1–18
198. Wolf RL, Alsop DC, Levy-Reis I et al (2001) Detection of mesial
temporal lobe hypoperfusion in patients with temporal lobe epi-
lepsy by use of arterial spin labeled perfusion MR imaging. AJNR
Am J Neuroradiol 22(7):1334–1341
199. Liu HL, Kochunov P, Hou J et al (2001) Perfusion-weighted im-
aging of interictal hypoperfusion in temporal lobe epilepsy using
FAIR-HASTE: comparison with H(2)(15)O PET measurements.
Magn Reson Med 45(3):431–435
200. Lim Y-M, Cho Y-W, Shamim S et al (2008) Usefulness of pulsed
arterial spin labeling MR imaging in mesial temporal lobe epilep-
sy. Epilepsy Res 82(2–3):183–189
201. Pizzini F, Farace P, Zanoni T et al (2008) Pulsed-arterial-spin-
labeling perfusion 3T MRI following single seizure: a first case
report study. Epilepsy Res 81(2–3):225–227
202. Pollock JM, Deibler AR, West TG et al (2008) Arterial spin-
labeled magnetic resonance imaging in hyperperfused seizure fo-
cus: a case report. J Comput Assist Tomogr 32(2):291–292
203. Pendse N,WissmeyerM, Altrichter S et al (2010) Interictal arterial
spin-labeling MRI perfusion in intractable epilepsy. J Neuroradiol
37(1):60–63
204. Wissmeyer M, Altrichter S, Pereira VM et al (2010) Arterial spin-
labeling MRI perfusion in tuberous sclerosis: correlation with
PET. J Neuroradiol 37(2):127–130
205. Storti SF, Boscolo Galazzo I, Del Felice A et al (2014) Combining
ESI, ASL and PET for quantitative assessment of drug-resistant
focal epilepsy. Neuroimage 102(Pt 1):49–59
206. Pizzini FB, Farace P, Manganotti P et al (2013) Cerebral perfusion
alterations in epileptic patients during peri-ictal and post-ictal
phase: PASL vs DSC-MRI. Magn Reson Imaging 31(6):1001–
1005
207. ToledoM,Munuera J, Salas-PuigX et al (2011) Localisation value
of ictal arterial spin-labelled sequences in partial seizures.
Epileptic Disord 13(3):336–339
208. Oishi M, Ishida G, Morii K et al (2012) Ictal focal hyperperfusion
demonstrated by arterial spin-labeling perfusion MRI in partial
epilepsy status. Neuroradiology 54(6):653–656
209. Kanazawa Y, Morioka T, Arakawa S et al (2015) Nonconvulsive
partial status epilepticus mimicking recurrent infarction revealed
by diffusion-weighted and arterial spin labeling perfusion magnet-
ic resonance images. J Stroke Cerebrovasc Dis 24(4):731–738
210. Van PaesschenW (2004) Ictal SPECT. Epilepsia 45(Suppl 4):35–40
211. Madan N, Grant PE (2009) New directions in clinical imaging of
cortical dysplasias. Epilepsia 50(Suppl 9):9–18
212. Théberge J (2008) Perfusion magnetic resonance imaging in psy-
chiatry. Top Magn Reson Imaging 19(2):111–130
213. Duhameau B, Ferré J-C, Jannin P et al (2010) Chronic and
treatment-resistant depression: a study using arterial spin labeling
perfusion MRI at 3 tesla. Psychiatry Res 182(2):111–116
214. Ho TC, Wu J, Shin DD et al (2013) Altered cerebral perfusion in
executive, affective, and motor networks during adolescent depres-
sion. J Am Acad Child Adolesc Psychiatry 52(10):1076–1091.e2
215. Colloby SJ, FirbankMJ, He J et al (2012) Regional cerebral blood
flow in late-life depression: arterial spin labelling magnetic reso-
nance study. Br J Psychiatry 200(2):150–155
216. Scheef L, Manka C, Daamen M et al (2010) Resting-state perfu-
sion in nonmedicated schizophrenic patients: a continuous arterial
spin-labeling 3.0-T MR study. Radiology 256(1):253–260
217. Pinkham A, Loughead J, Ruparel K et al (2011) Resting quantita-
tive cerebral blood flow in schizophrenia measured by pulsed
arterial spin labeling perfusionMRI. Psychiatry Res 194(1):64–72
218. Kindler J, Jann K, Homan P et al (2015) Static and dynamic
characteristics of cerebral blood flow during the resting state in
schizophrenia. Schizophr Bull 41(1):163–170
219. Wolf RC, Thomann PA, Sambataro F et al (2012) Orbitofrontal
cortex and impulsivity in borderline personality disorder: an MRI
study of baseline brain perfusion. Eur Arch Psychiatry Clin
Neurosci 262(8):677–685
220. Weiduschat N, Dubin MJ (2013) Prefrontal cortical blood flow
predicts response of depression to RTMS. J Affect Disord
150(2):699–702
221. Homan P, Kindler J, Hauf M et al (2012) Cerebral blood flow
identifies responders to transcranial magnetic stimulation in audi-
tory verbal hallucinations. Transl Psychiatry 2, e189
222. Handley R, Zelaya FO, Reinders AATS et al (2013) Acute effects
of single-dose aripiprazole and haloperidol on resting cerebral
blood flow (RCBF) in the human brain. Hum Brain Mapp 34(2):
272–282
223. Nordin LE, Li T-Q, Brogren J et al (2013) Cortical responses to
amphetamine exposure studied by PCASL MRI and
pharmacokinetic/pharmacodynamic dose modeling. Neuroimage
68:75–82
224. Khalili-Mahani N, NiestersM, vanOschMJ et al (2015) Ketamine
interactions with biomarkers of stress: a randomized placebo-
controlled repeated measures resting-state fMRI and PCASL pilot
study in healthy men. Neuroimage 108:396–409
225. Hendrikse J, van der Grond J, Lu H et al (2004) Flow territory
mapping of the cerebral arteries with regional perfusion MRI.
Stroke 35(4):882–887
226. Hartkamp NS, Helle M, Chappell MA et al (2014) Validation of
planning-free vessel-encoded pseudo-continuous arterial spin la-
beling MR imaging as territorial-ASL strategy by comparison to
super-selective P-CASL MRI. Magn Reson Med 71(6):2059–
2070
227. Hartkamp NS, Petersen ET, De Vis JB et al (2013) Mapping of
cerebral perfusion territories using territorial arterial spin labeling:
techniques and clinical application. NMR Biomed 26(8):901–912
1202 Neuroradiology (2015) 57:1181–1202
